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Abstract 17 
Coupling of endoplasmic reticulum stress to dimerisation-dependent activation of the UPR 18 
transducer IRE1 is incompletely understood. Whilst the luminal co-chaperone ERdj4 19 
promotes a complex between the Hsp70 BiP and IRE1’s stress-sensing luminal domain 20 
(IRE1LD) that favours the latter’s monomeric inactive state and loss of ERdj4 de-represses 21 
IRE1, evidence linking these cellular and in vitro observations is presently lacking. We report 22 
that enforced loading of endogenous BiP onto endogenous IRE1α repressed UPR signalling 23 
in CHO cells and deletions in the IRE1α locus that de-repressed the UPR in cells, encode 24 
flexible regions of IRE1LD that mediated BiP-induced monomerisation in vitro. Changes in the 25 
hydrogen exchange mass spectrometry profile of IRE1LD induced by ERdj4 and BiP 26 
confirmed monomerisation and were consistent with active destabilisation of the 27 
IRE1LD dimer. Together, these observations support a competition model whereby waning 28 
ER stress passively partitions ERdj4 and BiP to IRE1LD to initiate active repression of UPR 29 
signalling. 30 
 31 
32 
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Introduction 33 
In eukaryotes, the endoplasmic reticulum (ER) is the central organelle for the synthesis of 34 
proteins destined for secretion and membrane insertion. The ER lumen harbours a 35 
specialised protein folding and processing machinery that constitutes the protein folding 36 
capacity of the ER. To ensure that the environment for productive protein maturation is 37 
maintained, both folding capacity and the inward flux of newly synthesised proteins are 38 
regulated by a pervasive negative feedback signalling pathway, the unfolded protein 39 
response (UPR) (Kozutsumi et al., 1988; Cox et al., 1997). In mammalian cells, this pathway 40 
involves three known signalling branches each directed by a unique signal transducer 41 
resident in the ER membrane, IRE1, PERK and ATF6. An imbalance between folding load 42 
and capacity (ER stress) activates these sensors initiating a rectifying transcriptional and 43 
translational response to defend protein-folding homeostasis in the compartment (reviewed 44 
in Walter and Ron, 2011). While details of downstream events and their physiological 45 
significance are relatively well characterised (reviewed in Wang and Kaufman, 2016), the 46 
molecular mechanisms of the earliest events in UPR activation remain incompletely 47 
understood. 48 
IRE1, conserved in all eukaryotes and therefore the best-studied UPR transducer (Cox et al., 49 
1993; Mori et al., 1993), detects ER stress via its luminal domain (IRE1LD), initiating 50 
dimerisation-dependent autophosphorylation of its cytosolic domain (Shamu and Walter, 51 
1996). The subsequent allosteric activation of the cytosolic endoribonuclease domain (Lee et 52 
al., 2008) leads to unconventional splicing of the mRNA encoding the XBP1/HAC1 53 
transcription factor (Cox and Walter, 1996; Yoshida et al., 2001; Calfon et al., 2002), thereby 54 
promoting translation of an effector that drives a conserved gene-expression program. 55 
Two models have been put forth to describe how IRE1LD senses ER stress. A direct binding 56 
model posits that unfolded proteins act as ligands stabilising IRE1’s dimeric/oligomeric state 57 
thereby promoting its activation. This model is supported by the crystal structure of the core 58 
luminal domain from S. cerevisae IRE1, showing an IRE1LD dimer interface traversed by a 59 
groove with architectural similarity to the major histocompatibility peptide-binding complexes 60 
(MHCs) (Credle et al., 2005). Peptide ligands of the yeast IRE1LD have been identified and 61 
their addition to dilute solutions of yeast IRE1LD enhances the population of higher order 62 
species, although a clear shift from monomers to dimers was not readily observable 63 
(Gardner and Walter, 2011).  64 
The luminal domain of the broadly expressed alpha isoform of human IRE1 (hIRE1αLD) also 65 
crystallises as a dimer, with an overall architecture similar to the yeast protein, however, 66 
barring conformational changes, the MHC-like groove is too narrow to accommodate a 67 
peptide (Zhou et al., 2006). Recently, peptides have been identified that bind hIRE1LD and 68 
affect its oligomeric state, as assessed by analytical ultracentrifugation (AUC). Moreover, 69 
nuclear magnetic resonance (NMR) reported on peptide-induced structural rearrangements 70 
within the hIRE1αLD that also affected residues near the MHC-like groove. Hence, it has 71 
been proposed that the structure of Zhou et al. (2006) represents a ‘closed’ conformation of 72 
the peptide-binding groove that can shift towards an ‘open’ state to allow peptide binding 73 
(Karagoz et al., 2017). However, a co-crystal structure of the ligand-bound yeast or human 74 
IRE1LD is not available and it remains unclear if and how peptide ligands affect hIRE1LD 75 
dimerisation, the first crucial step of its activation.  76 
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An alternative hypothesis posits that IRE1 is repressed by interacting with a major 77 
component of the ER folding machinery, the heat shock protein (Hsp70) chaperone BiP. It is 78 
proposed that upon stress, unfolded proteins accumulate and compete for BiP interaction, 79 
thereby kinetically disrupting the inhibitory IRE1-BiP complex. This chaperone inhibition 80 
model draws parallels between the regulation of the UPR and its cytosolic counterpart, the 81 
heat shock response, in which chaperones associate with the transcription factor Hsf1, in 82 
eukaryotes, and σ32, in bacteria, to interfere with their activity (Abravaya et al., 1992; Shi et 83 
al., 1998; Tomoyasu et al., 1998). This model is supported by an inverse correlation between 84 
ER stress-induced IRE1 activity and the amount of ER-localised BiP recovered in complex 85 
with it (Bertolotti et al., 2000; Okamura et al., 2000; Oikawa et al., 2009). 86 
Further molecular insight into the chaperone inhibition mechanism was gained recently by 87 
the discovery of ERdj4 as an ER-localised J-domain protein that selectively represses IRE1 88 
activity in vivo and loads BiP onto the IRE1LD, thereby promoting monomerisation in vitro 89 
(Amin-Wetzel et al., 2017). Whilst other modes of BiP binding to the IRE1LD have been 90 
proposed (Carrara et al., 2015; Kopp et al., 2018) the aforementioned observations suggest 91 
a mechanism in which BiP engages the IRE1LD as an Hsp70 substrate: ATP-bound BiP 92 
initially interacts with the IRE1LD with high kon and high koff rates and only captures its 93 
substrate (in the ADP bound state, with low koff rates) after ERdj4 co-chaperone-instructed 94 
ATP hydrolysis. This model draws on the conventional view whereby J-domain proteins act 95 
as adaptors that enable efficient substrate recognition via their divergent targeting domains 96 
and subsequent binding of Hsp70s, promoted by their conserved J-domain that stimulates 97 
Hsp70’s ATPase activity (reviewed in Kampinga and Craig, 2010). J-domain co-chaperones 98 
act in concert with nucleotide exchange factors (NEFs, reviewed in Behnke et al., 2015) to 99 
accelerate Hsp70s’ cycles of substrate binding and release, resulting in substrate-selective 100 
ultra-affinity (Misselwitz et al., 1998; De Los Rios and Barducci, 2014), which is the basis for 101 
the assembly of Hsp70-substrate complexes.  102 
Whilst ERdj4’s repressive action on IRE1 signalling in cells and its ability to promote a 103 
complex between IRE1LD and BiP that favours the former’s monomeric state in vitro fit the 104 
chaperone inhibition model, they remain correlative findings and may be causally unrelated. 105 
For example, it is possible that ERdj4’s repressive action in cells arises from its role in 106 
eliminating IRE1LD activating ligands and not from catalysing the repressed, monomeric 107 
IRE1LD-BiP complex observed in vitro. Here, in support of the chaperone inhibition model, 108 
we report that enforced targeting of endogenous BiP to endogenously-expressed IRE1LD 109 
represses UPR signalling in cells, thereby establishing that BiP can directly repress IRE1 in 110 
vivo and that features of the IRE1LD that specify its repression in cells also specify its ability 111 
to undergo actively-driven monomerisation by ERdj4 and BiP in vitro.  112 
IRE1 Monomerisation (V41.1) 
 5 
Results 113 
BiP binding to IRE1LD represses IRE1 activity in cells 114 
An inverse correlation between ER stress-induced IRE1 activity and the amount of BiP 115 
recovered in complex with it has been previously observed (Bertolotti et al., 2000; Okamura 116 
et al., 2000; Oikawa et al., 2009) but a causal link between BiP binding and IRE1 activity 117 
status had never been conclusively established. To assess the effect of BiP binding on the 118 
activity of IRE1 in vivo, we modified the endogenous Ern1 locus to encode an ER targeted 119 
J-IRE1 fusion protein consisting of IRE1α’s endogenous signal peptide, an N-terminally 120 
fused J-domain (derived from ERdj4) followed by the endogenous IRE1α coding sequence 121 
(Fig. 1, supplement 1). The alpha isoform accounts for all measurable activity in CHO cells 122 
and is referred to as IRE1 hereafter. By employing this fusion protein, we expected to 123 
stimulate BiP’s ATPase activity in close proximity to the IRE1LD thereby promoting formation 124 
of an IRE1-BiP complex. As control, a point mutant ERdj4 J-domain was used that had the 125 
histidine of the highly conserved HPD motif replaced by glutamine (JQPD) compromising the 126 
stimulation of BiP‘s ATPase activity (Wall et al., 1994). The glycine-phenylalanine-rich (G/F) 127 
region of ERdj4 was included as a flexible linker, to allow the J-domain to explore the entire 128 
surface of IRE1LD. We deemed that low level expression of endogenous IRE1 (and hence 129 
J-IRE1) would minimise IRE1-independent effects of this chimeric J-domain protein on the 130 
ER folding environment, effects that could not be excluded as having contributed to the 131 
previously-noted repressive effect of ERdj4 over-expression on the UPR (Amin-Wetzel et al., 132 
2017). 133 
Using an Ern1 null cell line with a genomic deletion encompassing the IRE1LD-encoding 134 
exons 2-12 (ΔIRE1, previously described in Kono et al., 2017) we reconstituted the 135 
endogenous locus with either wild-type IRE1, J-IRE1 or JQPD-IRE1 fusion. Additionally, the 136 
cell lines stably expressed XBP1s::Turquoise and CHOP::GFP reporters that are controlled 137 
by the IRE1 and PERK UPR branches, respectively. Flow cytometry analysis showed that 138 
reconstitution of the locus with wild-type IRE1 rescues the non-responsive XBP1s::Turquoise 139 
phenotype of the ΔIRE1 cells towards stress induced by tunicamycin (Fig. 1A). In 140 
comparison, cells expressing the J-IRE1 fusion showed low XBP1::Turquoise reporter levels, 141 
indicating repressed IRE1 activity, even under stress. Repression was dependent on the 142 
integrity of the J-domain as ΔIRE1 cells reconstituted with the mutant JQPD-IRE1 acquired 143 
nearly wild-type stress responsiveness. The J-IRE1 protein was not otherwise compromised, 144 
as it was still able to respond to the ER stressor SubA, a protease that inactivates BiP by 145 
cleaving its interdomain linker (Paton et al., 2006) (Fig. 1B). These findings are consistent 146 
with BiP serving as a direct trans-acting factor to specify repression mediated by a J-domain 147 
presented in cis to the IRE1LD. 148 
A role for the cis-active J-domain in recruiting BiP to the IRE1LD is supported by 149 
immunoprecipitation (IP) of endogenous IRE1 prepared from the cells described above. 150 
More BiP was recovered in complex with the J-IRE1 chimera compared to the wild-type 151 
IRE1 whilst the mutant JQPD-IRE1 fusion associated with a similar amount of BiP as the 152 
wild-type (Fig. 1C), which is in accordance to their similar phenotype detected by flow 153 
cytometry. 154 
To further validate these in vivo observations, we reconstituted the system in vitro using 155 
recombinant proteins purified from bacteria. First, pull down of either C-terminally 156 
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biotinylated IRE1LD (IRE1LD-bio) or J-IRE1LD (J-IRE1LD-bio) was performed. We assessed the 157 
formation of a BiP-IRE1LD-bio complex on SDS-PAGE after recovery on immobilised 158 
streptavidin (Fig. 1D). Whilst BiP recovery in complex with IRE1LD-bio was dependent on the 159 
presence of both ERdj4 and ATP in the binding assay, complex formation of BiP and 160 
J-IRE1LD-bio required only ATP.  161 
Next, we tested how BiP binding affected J-IRE1LD’s oligomeric status in vitro using a Förster 162 
resonance energy transfer (FRET)-based assay to continuously monitor the monomer-dimer 163 
equilibrium (as described previously, Amin-Wetzel et al., 2017). A donor IRE1LD labelled with 164 
Oregon Green (OG) was pre-equilibrated either with an IRE1LD or J-IRE1LD acceptor 165 
molecule labelled with TAMRA (TMR). As previously observed, BiP, ERdj4, and ATP were 166 
all required to monomerise the IRE1LD homodimer as reflected in the time-dependent 167 
increase in donor fluorescence until a kinetically maintained pseudo steady state was 168 
reached (Fig. 1E). In contrast, heterodimeric FRET pairs containing the J-IRE1LD fusion and 169 
IRE1LD were monomerised by BiP in an ATP-dependent manner, but did not require ERdj4 170 
in trans. The nucleotide-dependent, BiP-induced monomerisation of the J-IRE1LD containing 171 
heterodimer occurred with an approximately four-fold higher initial velocity and a higher 172 
plateau in the pseudo steady state of the reaction. Taken together these findings suggest 173 
that the fused J-domain enables efficient formation of the IRE1LD-BiP complex, thereby 174 
promoting monomerisation, which leads to repression of IRE1 activity.  175 
In vitro characterisation of direct binding of unfolded proteins to IRE1LD as modelled 176 
by the MPZ-N peptide 177 
To examine the role of peptides in regulating the monomer-dimer equilibrium of IRE1LD and 178 
hence its activity, we turned to a 12-mer peptide (MPZ-N) derived from myelin protein zero. 179 
MPZ-N is the best studied ligand for mammalian IRE1LD and was recently proposed to 180 
directly interact with the peptide-binding groove thereby influencing IRE1LD‘s oligomeric 181 
status (Karagoz et al., 2017). When introduced into the FRET-based assay, MPZ-N had no 182 
measurable effect on donor fluorescence. However, as the optical readout of this assay is 183 
sensitive mostly to monomerisation (as reflected in an increase in donor fluorescence, 184 
Fig. 1E) it would be a relatively insensitive measure of MPZ-N peptide driven dimerisation. 185 
Therefore, we sought different assays to report on the ability of the MPZ-N peptide to 186 
promote IRE1LD dimers. 187 
The distribution of IRE1LD between monomers and dimers can be tracked by size exclusion 188 
chromatography (SEC), as evidenced by the concentration-dependence of the peak elution 189 
time of IRE1LD and two dimerisation-compromised mutants: a previously characterised 190 
W125A variant (Zhou et al., 2006) and a new, more severe P108A variant (Fig. 2, 191 
supplement 1A). Both mutations are predicted to decrease hydrophobic interactions across 192 
the dimer interface (Fig. 2, supplement 1B). Addition of MPZ-N peptide (at concentrations 193 
exceeding the reported K1/2 max for binding of 16 µM, Karagoz et al., 2017) did not affect the 194 
peak elution time of IRE1LD, itself introduced into the assay at 500 nM, near the Kd for IRE1
LD 195 
dimerisation (Zhou et al., 2006) (Fig. 2A and 2B). 196 
To confirm these observations, we made use of an alternative assay reporting on IRE1LD’s 197 
dimerisation status. To this end, we employed a modified IRE1LD Q105C that forms a disulphide 198 
across the dimer interface, creating a covalently stabilised dimer when placed in oxidising 199 
conditions (Fig. 2, supplement 1C) and the aforementioned dimerisation-compromised 200 
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versions of the IRE1LD (W125A and P108A). Differential scanning fluorimetry (DSF) revealed 201 
that the melting temperature (Tm) of disulphide-linked IRE1
LD Q105C SS was ~10˚C higher than 202 
the one of the wild-type protein, a Tm difference that was effaced by reduction of the dimer-203 
stabilising disulphide (Fig. 2, supplement 1D). By contrast, the IRE1LD monomeric variants 204 
exhibited a Tm 5-10˚C lower than the wild-type. These observations established a correlation 205 
between the monomer-dimer equilibrium and the Tm of the protein consistent with 206 
dimerisation-mediated stabilisation of the IRE1LD. A ligand, stabilising the IRE1LD dimer, is 207 
predicted to increase the Tm, however, addition of MPZ-N peptide had no effect on the Tm of 208 
IRE1LD (Fig. 2, supplement 1D, the significance of the lowering of Tm observed at the highest 209 
concentrations of peptide remains to be determined).  210 
To gain insight into the mode of MPZ-N binding to IRE1LD we made further use of the 211 
disulphide-linked IRE1LD Q105C SS. The crystallised IRE1LD Q105C SS dimer proved identical in 212 
structure to the wild-type protein (root-mean squared deviation (RMSD) of 0.46 Å over 213 
227 Cα atoms) except for the presence of a conspicuous density corresponding to a C105-214 
C105 trans-protomer disulphide thereby locking the proposed binding groove in the ‘closed’ 215 
conformation (Fig. 2C, Figure 2, supplement 1E and Table 1). Nonetheless, a fluorescence 216 
polarisation binding assay, using FAM-labelled MPZ-N, showed that binding to the IRE1LD 217 
was not compromised by the disulphide (Fig. 2D), leading us to conclude that MPZ-N does 218 
not obligatorily bind within the proposed MHC-like groove of the IRE1LD. This conclusion is 219 
also consistent with the paramagnetic relaxation enhancement (PRE) experiments with 220 
IRE1LD and an MPZ-proxyl-labelled peptide (Karagoz et al., 2017), which present a distance 221 
constraint of 10 Å between Ile186 of the IRE1LD and the labelled Cys5 of the peptide. Fig. 2, 222 
supplement 2 shows that the extended peptide is free to explore the entire surface of one 223 
face of the IRE1LD and may therefore bind in locations other than the MHC-like groove, 224 
without violating this distance constraint.  225 
Identification of regions in IRE1LD involved in BiP-mediated regulation of its activity 226 
Given the evidence for BiP’s role in IRE1 repression, we tried to identify regions in IRE1LD 227 
that might be important for such regulation. BiP, as an Hsp70 chaperone, typically interacts 228 
with unfolded or flexible regions in its client proteins (Rudiger et al., 1997) and we held that 229 
this might also be the case for its interaction with the IRE1LD. Therefore, we sought clues to 230 
map these flexible regions by collecting data on the structural dynamics of IRE1LD in solution 231 
as evaluated by hydrogen-1H/2H-exchange experiments in combination with mass 232 
spectrometry (HX-MS).  233 
IRE1LD was pre-equilibrated for 30 minutes at 30°C followed by an exchange reaction in 234 
deuterium oxide (D2O) buffer for 30 and 300 seconds. Subsequent analysis of deuteron 235 
incorporation was performed as described previously (Hentze and Mayer, 2013). Information 236 
on peptic peptides covering 85% of the IRE1LD sequence was obtained (Table 2). The 237 
extracted percentage of exchange (%ex) for each peptic peptide contained information about 238 
the thermodynamic stability of structural elements, the hydrogen bonding and solvent 239 
accessibility of backbone amide hydrogens (Fig. 3A left panel). Projection of these values 240 
onto the crystal structure showed that regions in the hydrophobic core exhibited significant 241 
protection from exchange (low %ex), whereas surface exposed areas were more dynamic 242 
(high %ex) (Fig. 3A right panel). This method identified the region encompassing residues 243 
303-378 as being especially flexible, a conclusion consistent with the observation that 244 
though it was present in the constructs used for crystallisation, residues 308-357 were 245 
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resolved in neither the crystal structures of wild-type IRE1LD (Zhou et al., 2006) (Fig. 3A right 246 
panel dotted line) nor the disulphide-linked IRE1LD Q105C SS variant here. Similar 247 
characteristics apply to residues 379-444, covering the so-called tail region that connects the 248 
structured core of the IRE1LD with the transmembrane domain (Fig. 3A right panel dotted line 249 
and Fig. 3, supplement 1A). Moreover, the latter residues overlap with a region of IRE1LD 250 
implicated in its basal repression in an overexpression cell-based assay (Oikawa et al., 251 
2007; Oikawa et al., 2009). 252 
To probe the putative loop (residues 308-357) and the tail region (residues 390-444) for their 253 
importance in maintaining the repressed state of IRE1 in vivo we devised a CRISPR-Cas9 254 
mutagenesis strategy (Fig. 3B). By targeting only unstructured regions within IRE1LD we 255 
hoped to preserve the integrity of the core structure whilst favouring mutations that might de-256 
repress IRE1 activity. After introducing a set of guide RNAs targeting the region of interest 257 
together with the Cas9 endonuclease into cells, error prone non-homologous end joining 258 
(NHEJ) resulted in a series of mutations, ranging from small in-frame indels at a single guide 259 
site to larger ones spanning two guide sites. The IRE1 reporter was used to select rare 260 
clones exhibiting a de-repressed IRE1 phenotype (XBP1s::Turquoise bright). The 261 
CHOP::GFP reporter was used to exclude clones exhibiting a general perturbation of ER 262 
protein homeostasis. Iterative rounds of fluorescence-activated cell sorting (FACS) enriched 263 
the XBP1s::Turquoise bright population. Clones that had acquired IRE1-independent 264 
XBP1s::Turquoise reporter expression were purged based on their unresponsiveness to the 265 
IRE1 inhibitor 4µ8c (Cross et al., 2012). The Ern1 locus of individual clones with deregulated 266 
IRE1 activity found in the final pool was sequenced (Fig 3C left panel). As expected, all the 267 
putative deregulating deletions/mutations maintained the frame of the IRE1 coding sequence 268 
(Fig. 3C right panel and Figure 3, supplement 1B). These observations suggested that 269 
deletions of unstructured regions of IRE1LD could deregulate IRE1 activity. 270 
Characterisation of IRE1LD deletion constructs in vivo and in vitro 271 
To confirm the suggested role of deletions of the loop and the tail region of IRE1LD in 272 
deregulating its activity in cells, we reconstituted the endogenous Ern1 locus of the ∆IRE1 273 
cell line with the most extensive IRE1 deletion variants identified above: the Δloop (missing 274 
residues 313-338), the Δtail (missing residues 391-444) or both (ΔΔ). The reconstituted 275 
alleles de-repressed IRE1 activity, as indicated by the elevated basal XBP1s::Turquoise 276 
signal (Fig. 4A and Figure 4, supplement 1A). The IRE1 ΔΔ double deletion had the 277 
strongest deregulated phenotype under basal conditions. Like the shorter deletions, the 278 
IRE1 ΔΔ double deletion nonetheless retained some responsiveness to stress, albeit with a 279 
narrowed dynamic range (Fig. 4A, compare untreated to tunicamycin treated samples).  280 
To establish if the deregulating deletion affected the association of the IRE1LD with BiP, we 281 
compared the amount of BiP that co-immunoprecipitated with the endogenously expressed 282 
wild-type or IRE1 ΔΔ (Fig. 4B). Despite variation in the total BiP signal intensity in the three 283 
independent repeats (Fig. 4B, lower panel), paired analysis revealed that significantly less 284 
BiP was associated with the IRE1 ΔΔ mutant. The same was observed in a transient 285 
transfection system in which IRE1’s cytosolic effector domains were replaced with 286 
glutathione S-transferase (GST). Compared to the wild-type IRE1LD-GST bait, the amount of 287 
BiP recovered by glutathione affinity chromatography in association with the variants was 288 
significantly lower in context of the single deletions and even lower in case of the double-289 
deletion IRE1LD ΔΔ-GST (Fig. 4C).  290 
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Together, the observations described above confirm a role for the flexible regions of the 291 
IRE1LD in maintaining IRE1 in a repressed state in vivo and suggest that such repression 292 
may reflect a role for these flexible regions in specifying BiP binding. To follow up on this 293 
suggestion, Bio-Layer Interferometry (BLI) was used to compare BiP’s association with the 294 
biotinylated wild-type or double-deleted IRE1LD ∆∆ immobilised on the sensor. Immersing the 295 
sensor into a solution containing ERdj4, BiP and ATP gave rise to an association curve, that 296 
was reproducibly attenuated when IRE1LD ΔΔ was bound as a ligand compared to the 297 
wild-type IRE1LD (Fig. 5, supplement 1A, left traces). A similar qualitative defect in BiP 298 
binding to IRE1LD ΔΔ was also observed when the full-length ERdj4 was replaced by its 299 
isolated J-domain (that lacks the regions required for specific targeting to the IRE1LD) (Fig. 5, 300 
supplement 1A, right traces).  301 
This last observation suggested that the defect in J-domain-mediated BiP binding to 302 
IRE1LD ΔΔ, had a component that was independent of recruitment of ERdj4 to IRE1LD by the 303 
former’s targeting domain and implied that the deleted region of IRE1LD had a role in 304 
specifying BiP association. This was explored further using J-IRE1LD fusion proteins as BLI 305 
ligands to enforce ATP hydrolysis by BiP in proximity to the wild-type or double-deleted 306 
IRE1LD (independent of the role these flexible regions of IRE1LD might have in J-domain co-307 
chaperone recruitment). Immersing a BLI sensor loaded either with J-IRE1LD or J-IRE1LD ΔΔ 308 
into a solution containing BiP and ATP revealed a reproducible defect of BiP association to 309 
J-IRE1LD ΔΔ (Fig. 5A left panel). No association was observed in presence of the substrate 310 
binding-deficient BiPV461F mutant. The dissociation in presence of ATP remained similar for 311 
both wild-type and J-IRE1LD ΔΔ (Fig. 5A right panel), as expected of a process limited by 312 
BiP’s rate of nucleotide exchange.  313 
The measurements above report on BiP’s interaction with the IRE1LD in the context of 314 
J-domain-mediated, ATP hydrolysis-driven ultra-affinity (Misselwitz et al., 1998; De Los Rios 315 
and Barducci, 2014). To examine the role of IRE1LD’s flexible regions in its affinity for 316 
BiP-ADP (an interaction that reports on a segment of the ultra-affinity cycle) we combined 317 
BiP with C-terminally biotinylated IRE1LD (either IRE1LD-bio or IRE1LD ∆∆-bio) in presence of 318 
ADP and absence of J-domain protein. Given the slow association of BiP-ADP with 319 
substrates and the slow dissociation of BiP oligomers a lengthy equilibration (16 hours) was 320 
allowed. Almost three-fold less BiP was recovered in complex with IRE1LD ∆∆-bio than with 321 
IRE1LD-bio (Fig. 5B). BiP association was concentration-dependent, destabilised by ATP and 322 
was not observed with BiPV461F. Coupling of BiP’s two domains was dispensable for this 323 
interaction with IRE1LD-bio, as it was also observed with the domain-uncoupled BiPADDA 324 
(Preissler et al., 2015a). Together, these observations point to a role for the flexible regions 325 
of IRE1LD in specifying BiP association as a conventional substrate of this Hsp70. An 326 
additional role for the flexible regions in ERdj4 recruitment was not evident within the 327 
sensitivity of the tools available to us, and therefore remains unexcluded. 328 
BiP binding in vitro promotes dissociation of the IRE1LD dimer (Amin-Wetzel et al. 2017 and 329 
Fig. 1E). Therefore, we employed the same FRET-based assay to determine if impaired BiP 330 
binding affected monomerisation of IRE1LD ΔΔ -containing dimers. Wild-type fluorescent 331 
donor-labelled IRE1LD was allowed to dimerise with acceptor-labelled IRE1LD or IRE1LD ΔΔ 332 
and the rate at which BiP, ERdj4 and ATP promoted dissociation of these dimers was 333 
measured by following the increase in donor fluorescence over time. The initial velocity of 334 
BiP-mediated monomerisation of the IRE1LD ΔΔ containing heterodimers was considerably 335 
slower than monomerisation of wild-type homodimers (Fig. 5C).  336 
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In BLI experiments, BiP association to monomeric IRE1LD P108A was faster than to the 337 
enforced dimeric IRE1LD Q105C SS (Fig. 5, supplement 1B), raising the concern that both 338 
diminished BiP binding to the IRE1LD ΔΔ observed in BLI (Fig. 5A) and the slower 339 
monomerisation of the IRE1LD ΔΔ containing FRET pair (Fig. 5C) might reflect intrinsically 340 
enhanced stability of the IRE1LD ΔΔ-containing dimers. However, SEC of the purified proteins 341 
performed over a range of protein concentrations reported on similar affinities of the 342 
wild-type and IRE1LD ΔΔ dimers (Fig. 5, supplements 1C and 1D) yielding K1/2 max values in the 343 
same order of magnitude as the KD of dimerisation measured by AUC (Zhou et al., 2006). 344 
Together, these observations suggest that diminished BiP binding to IRE1LD ΔΔ resulted in an 345 
impairment of BiP-driven IRE1LD monomerisation.  346 
BiP-driven monomerisation of IRE1LD assessed by HX-MS  347 
To complement the kinetic observations pointing to impaired BiP-driven monomerisation of 348 
IRE1LD ΔΔ with structural correlations, HX-MS was performed. To establish the HX-MS 349 
signature of monomerisation, deuteron incorporation was compared between wild-type and 350 
dimerisation-defective IRE1LD W125A or IRE1LD P108A mutants. This reported on 351 
monomerisation-induced deprotection of several peptic peptides from the IRE1LD (Fig. 6A). 352 
Projecting these areas onto the crystal structure revealed that monomerisation affected HX 353 
at the dimer interface but also in parts further away (Fig. 6B). IRE1LD monomerisation thus 354 
induced structural rearrangements across the protein. Moreover, the difference plot in HX 355 
reported on a gradation between both mutant variants, as IRE1LD P108A had an enhanced 356 
signature of monomerisation compared to IRE1LD W125A, matching the hierarchy of dimer 357 
instability observed by SEC and DSF analysis (Fig. 2, supplements 1A and 1D, 358 
respectively). 359 
A similar deprotection signature, affecting most of the peptic peptides that are exposed upon 360 
monomerisation, was observed when IRE1LD was incubated with BiP and ERdj4 in presence 361 
of ATP (Fig. 6C upper row, box 1: residues 77-128 and box 2: residues 280-302). 362 
Monomerisation was dependent on the integrity of all components of the reaction, as neither 363 
the substrate binding BiPV461F mutant nor the ERdj4QPD supported the pattern of deprotection 364 
observed in the monomeric versions of IRE1LD (the significance of the protection afforded by 365 
BiPV461F and ERdj4QPD to some peptides is presently unknown). IRE1LD ΔΔ exhibited delayed 366 
monomerisation in presence of BiP, ERdj4 and ATP: IRE1LD ΔΔ’s signature of 367 
monomerisation was absent after 30 seconds incubation in D2O (Fig. 6C lower row) and was 368 
faint even after an exchange reaction of 300 seconds (Fig. 6, supplements 1B and 1C lower 369 
row). In the absence of BiP, ERdj4 and ATP the difference plot comparing deuteron 370 
incorporation into IRE1LD and IRE1LD ΔΔ was negligible (Fig. 6, supplement 1D) providing 371 
independent confirmation of the SEC measurements pointing to similar stability of the 372 
wild-type and IRE1LD ΔΔ mutant dimer (Fig. 5, supplements 1C and 1D). Thus, HX-MS 373 
provided an orthogonal assay to the FRET-based measurement, reporting on BiP-mediated 374 
monomerisation of IRE1LD and a kinetic defect in this process brought about by deletion of 375 
flexible regions in the luminal domain that enforce IRE1’s repressed state in cells. 376 
Close inspection of the HX-MS data revealed that some of the peptides (e.g. peptides 377 
636.3802+ and 655.273+ corresponding to residues 96-106 and 297-302, respectively) 378 
exhibited clear bimodal isotope distribution. This characteristic is a signature for the EX1 379 
exchange regime, indicative of the presence of two discrete subpopulations of molecules: a 380 
more folded and therefore low exchanging subpopulation and a more open, high exchanging 381 
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subpopulation (Fig. 7, supplement 1A and methods section). The contribution of low and 382 
high exchanging subpopulations to each isotope peak was determined by fitting the isotope 383 
peak maxima versus m/z data points (Fig. 7A) to a two Gaussian distribution model (Hentze 384 
et al., 2016). From the fit parameters the fraction of each isotope peak that belongs to the 385 
low and high exchanging subpopulation was calculated [Fig. 7, supplements 1A (blue and 386 
red parts of the bars) and 1B]. Comparison with the unexchanged and the 100% control 387 
samples revealed that the low exchanging subpopulation was largely protected from HX, 388 
whereas the high exchanging subpopulation had almost all amide protons exchanged for 389 
deuterons. Moreover, the low exchanging subpopulation converted into the high exchanging 390 
subpopulation with time (Fig. 7, supplement 1A, compare 30 and 300 seconds incubation in 391 
D2O).  392 
Interestingly, the degree of conversion into the high exchanging subpopulation was more 393 
pronounced for the IRE1LD P108A monomeric mutant than for wild-type IRE1LD and essentially 394 
complete after 300 seconds (Fig. 7, supplement 1A left panel). SEC analysis of IRE1LD P108A 395 
showed that at 5 µM (the concentration at which the protein was diluted into D2O) it is mostly 396 
monomeric (Fig. 2, supplement 1A). Hence, these data suggest that the conversion from the 397 
low exchanging subpopulation to the high exchanging subpopulation was a feature of the 398 
monomeric state.  399 
HX is a quasi-irreversible reaction: Once a molecule has transiently assumed a high 400 
exchanging conformation (and undergone the exchange) the signature of having transited 401 
through a high exchanging conformation remains even if the protein is in a conformational 402 
equilibrium (and individual molecules transit back to the low exchanging conformation). 403 
Thus, HX-MS detects the transition to the high exchange endpoint. The observation that for 404 
wild-type IRE1LD the transition from the low (blue) to the high (red) exchanging population 405 
occurred with much slower kinetics than for IRE1LD P108A (Fig. 7, supplement 1A, compare left 406 
panel, monomeric IRE1LD P108A with the right panel, wild-type IRE1LD) suggests that a higher 407 
proportion of IRE1LD monomers increased the transition rate, whereas the presence of 408 
IRE1LD dimers leads to a reduction of the rate constant. Hence, the extracted transition rate 409 
ktrans reports on IRE1
LD’s monomer-dimer equilibrium during the reaction.  410 
Next, we compared the ktrans of peptic peptide 655.273
+ from wild-type IRE1LD in presence 411 
and absence of BiP, ERdj4 and ATP. Due to pre-incubation of the reactions, the 412 
three-protein system already had a higher proportion of monomeric IRE1LD at the point of 413 
dilution into D2O (reflected in a greater proportion of the high mass population at the earliest 414 
measurement). Nevertheless, an accelerated time-dependent increase in the proportion of 415 
monomeric IRE1LD was observed in the BiP-treated sample, indicating an increase in ktrans 416 
(Fig. 7A and 7B). Acceleration of ktrans was also observed with peptide 636.380
2+ in presence 417 
of BiP, ERdj4 and ATP (Fig. 7C and Figure 7, supplement 1C).  418 
Because it is affected by peptide-specific flexibility, ktrans itself is not a direct measure of the 419 
first order dissociation rate of the IRE1LD dimer (its koff), however, the difference observed in 420 
ktrans for any individual peptide measured under two conditions mainly reports on differences 421 
in IRE1LD dimer dissociation. Therefore, these findings imply that BiP-induced IRE1LD 422 
monomerisation has a component arising from active destabilisation of the dimer.  423 
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Discussion 424 
The notion that a chaperone machinery with an Hsp70, such as BiP, as its terminal effector 425 
might negatively regulate activity of an upstream UPR transducer, such as IRE1, has the 426 
appeal of simplicity: Hsp70’s can potently affect the structure and function of their clients. 427 
The level of free BiP is kept low by inactivating oligomerisation and AMPylation and is further 428 
limited by client titration (Preissler and Ron, 2019). Therefore, the availability of a BiP-429 
dependent machinery to serve as an active repressor of IRE1 is a plausible inverse measure 430 
of the level of ER stress. For years, the inverse relationship between the recovery of BiP in 431 
complex with IRE1 and exposure of cells to conditions causing ER stress has provided the 432 
only experimental support for this chaperone repression model (Bertolotti et al., 2000; 433 
Okamura et al., 2000; Oikawa et al., 2009). The recent establishment of an ATP- and co-434 
chaperone-dependent system in which BiP promotes a pool of monomeric, inactive-state 435 
IRE1LD further supports the model by revealing BiP’s potential to affect a major change in 436 
IRE1’s activity in vitro (Amin-Wetzel et al., 2017). Here we provide much needed further 437 
support for the chaperone repression model by demonstrating that directing endogenous BiP 438 
to bind endogenous IRE1LD as a substrate also attenuates signalling in cells, thus revealing 439 
BiP’s potential as a direct IRE1 repressor in vivo.  440 
A structure-based targeted approach identified regions of IRE1LD that impart a repressed 441 
state in vivo. The same regions proved important for ATP and co-chaperone-dependent BiP-442 
mediated conversion of active-state IRE1LD dimers to inactive-state monomers in vitro and 443 
their presence accelerated the formation of an ATP and co-chaperone-dependent complex 444 
with BiP in vitro. Monomerisation was observed in both a FRET-based assay, involving 445 
labelled molecules of IRE1LD, and in an HX-MS assay with intact molecules, thus 446 
establishing a firm correlation between the determinants of IRE1 that regulate its function in 447 
vivo and those that specify its regulation in vitro by a BiP-led machinery (Fig. 8).  448 
Correlation between factors involved in BiP regulation of IRE1 in vitro and UPR activity in 449 
vivo have been previously noted: Deregulated AMPylation of BiP activates IRE1 in cells 450 
(Preissler et al., 2015b) and BiP AMPylation in vitro blocks IRE1LD monomerisation (Amin-451 
Wetzel et al., 2017). ERdj4 acts in concert with BiP to monomerise IRE1LD in vitro and loss 452 
of ERdj4 from cells de-represses IRE1 in vivo (Amin-Wetzel et al., 2017). However, genetic 453 
lesions in trans-acting ER-localised factors also have the potential to broadly alter the state 454 
of the ER and thereby unleash processes that affect IRE1 independently (of any direct 455 
interaction with BiP). Indirect effects are less likely a consequence when IRE1LD is modified 456 
in cis. Therefore, whilst it is impossible to rule out contributions from factors other than the 457 
BiP machinery to the deregulation of IRE1 that arises from deletion of the unstructured 458 
regions of its luminal domain, attenuation of BiP-mediated IRE1 repression in cells emerges 459 
as a parsimonious unifying explanation for the findings presented here.  460 
It is further notable that there is nothing in our observations to speak against the possibility 461 
that extended regions of unfolded ER proteins serve as activating ligands of IRE1 by binding 462 
across the IRE1LD dimer interface and stabilising it (Karagoz et al., 2019). IRE1 signalling is 463 
triggered by an imbalance between unfolded proteins and BiP. The latter results in more 464 
potential ligands for IRE1 and fewer molecules of its client-free ATP bound BiP repressor 465 
(Bakunts et al., 2017; Vitale et al., 2019). Thus, the two proposed mechanisms for IRE1 466 
activation, could well co-exist. However, our findings do raise questions regarding the 467 
strength of the experimental evidence supporting the current ideas how unfolded proteins 468 
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may serve as activating ligands of IRE1. The evidence rests prominently on the activity of a 469 
peptide, MPZ-N, nominated as a model activating ligand of IRE1LD (Karagoz et al., 2017). 470 
Our findings do not support the notion that this peptide specifically engages the MHC-like 471 
groove traversing the dimer interface, as a disulphide, crystallographically proven to lie 472 
across this groove, thereby locking the helices in a ‘closed’ conformation, had no effect on 473 
the binding of MPZ-N to IRE1LD. Furthermore, MPZ-N binding to IRE1LD did not stabilise it 474 
thermodynamically, whereas the aforementioned disulphide, which mimics the proposed 475 
dimer-stabilising effect of a bound peptide, increased the melting temperature IRE1LD by 476 
10˚C. Nor did MPZ-N promote a shift in the monomer-dimer equilibrium of IRE1LD as 477 
assessed by SEC. These concerns, along with the lack of crystallographic data supporting 478 
engagement of the groove by ligands, suggest the need for further experiments to test the 479 
role of unfolded proteins as direct IRE1 activators. 480 
HX-MS analysis revealed neither an ERdj4-dependent nor BiP and ATP-dependent 481 
protection within IRE1LD to suggest their binding site. It has been proposed that ERdj4’s 482 
bacterial homolog, DnaJ, exploits mostly side chain interactions to bind clients, with a strong 483 
preference for aromatic residues (Rudiger et al., 2001). Such interactions, were they to serve 484 
as the basis for IRE1LD recognition by ERdj4, would be only visible to HX-MS if they 485 
stabilised the underlying secondary structure. Given the conventional mode of BiP action on 486 
IRE1LD (ATP and co-chaperone-dependent and abolished by the BiPV461F mutation), one 487 
would expect protection of 4-5 hydrogen amides by IRE1LD engagement in the chaperone’s 488 
substrate binding domain. However, partial occupancy of multiple sites may have diluted any 489 
HX-MS signature of BiP binding. This is supported by the observation that at the 490 
concentrations of ERdj4 and BiP used in the HX-MS assay, the FRET assay reported peak 491 
florescence of only ~40% of the unquenched donor (at the kinetically-driven pseudo steady 492 
state plateau of the reaction, Fig. 1E). Thus, the lack of a clear ATP- and ERdj4-dependent 493 
BiP binding signature is consistent with the dynamic nature of BiP’s interaction with IRE1LD. 494 
Interestingly, we observed an ATP-independent protection against deuteron incorporation 495 
within IRE1LD that was even visible in presence of the substrate binding-defective BiPV461F. 496 
This might reflect a non-conventional interaction of BiP’s nucleotide binding domain with 497 
IRE1LD, as proposed by the Ali lab (Kopp et al., 2018; Kopp et al., 2019). However, this 498 
protection is not correlated to the activity-state of IRE1LD and its significance thus remains to 499 
be established. 500 
Mechanistically, BiP’s interaction with IRE1LD shares features with other situations in which 501 
Hsp70s bind to native clients thereby regulating their activity: DnaJ-directed, DnaK-mediated 502 
destabilisation of E. coli σ32 (Rodriguez et al., 2008), functional regulation of the 503 
glucocorticoid receptor (Kirschke et al., 2014), regulation of the activity of the tumour 504 
suppressor p53 (Boysen et al., 2019; Dahiya et al., 2019), Hsf1 regulated heat shock gene 505 
expression (Abravaya et al., 1992) and Hsc70-mediated destabilisation of clathrin coats 506 
(Sousa et al., 2016). All these have in common client destabilisation and likely initiate at 507 
unstructured regions of the substrate. Thus, it seems reasonable to suggest that an 508 
important aspect of BiP’s ability to affect the disposition of IRE1LD’s monomer-dimer 509 
equilibrium arises from its interaction with the flexible regions identified here.  510 
Bimodal analysis of the HX-MS data suggested that ERdj4-directed BiP binding can 511 
accelerate dimer disassembly. This is consistent with the ability of the IRE1LD dimer to serve 512 
as a ligand for ERdj4 and BiP (here and Amin-Wetzel et al., 2017). While BiP binding to and 513 
stabilisation of IRE1LD monomers may also contribute to shifting the monomer-dimer 514 
equilibrium toward the former, the HX-MS experiment suggests an (additional) active role for 515 
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BiP in dimer destabilisation. This may arise from a BiP-binding induced bias of the ensemble 516 
of IRE1LD dimers towards conformers preferentially populated in the monomer. A similar 517 
mechanism of conformational selection has been proposed for DnaK-mediated 518 
destabilisation of E. coli σ32 (Rodriguez et al., 2008). Such “allosteric” action is consistent 519 
with the observation that monomerisation has effects on IRE1LD structure that are far 520 
removed from the dimer interface. Alternatively, BiP binding may destabilise the IRE1LD 521 
dimer by entropic pulling (De Los Rios et al., 2006), as has been suggested in Hsc70-522 
mediated destabilisation of clathrin coats (Sousa et al., 2016) (Fig. 8). The latter mechanism 523 
would be further favoured by assembly of BiP oligomers on the surface of the IRE1LD, a 524 
possibility consistent with the >1:1 stoichiometry of BiP:IRE1LD complexes observed in some 525 
experiments (Amin-Wetzel et al., 2017) (though the latter may also reflect multiple BiP 526 
binding sites). 527 
As shown here, flexible regions of IRE1LD contribute measurably to its repression in cells and 528 
to BiP-driven monomerisation in vitro. This observation is consistent with the idea that these 529 
regions serve as initiation points for BiP binding to promote dimer disassembly via entropic 530 
pulling, allosterically induced conformational changes or both. Considerable redundancy 531 
seems built into the process, as the deregulated IRE1∆∆ allele retained a measure of stress 532 
responsiveness in cells and the IRE1LD ∆∆ dimer was still slowly undone in a BiP-dependent 533 
process in vitro. Such redundancy has been observed previously: in both yeast and human 534 
IRE1 deletion of the tail region connecting the structured core of IRE1LD to the 535 
transmembrane domain partially deregulated IRE1, whilst retaining partial responsiveness to 536 
ER stress (Oikawa et al., 2007; Oikawa et al., 2009). Redundancy in the structural features 537 
of the IRE1LD dimer that render it a substrate for BiP-dependent disassembly and the non-538 
equilibrium kinetic nature for BiP’s action could serve as the basis for a smoothly graded 539 
response to variation in the levels of ER stress.  540 
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Figure Legends 738 
Figure 1: Fusion of ERdj4’s J-domain to IRE1LD promotes efficient BiP association 739 
thereby repressing IRE1 activity in cells.  740 
(A) Two dimensional plots of CHOP::GFP and XBP1s::Turquoise signals from CHO-K1 dual 741 
UPR reporter cells stably expressing the indicated IRE1 variants [IRE1 wild-type (wt), J-IRE1 742 
or JQPD-IRE1 fusion; see Fig. 1, supplement 1A, for schema of the alleles] from the 743 
endogenous Ern1 locus untreated and treated with the ER stressor tunicamycin (Tm). 744 
Clones used for the analysis were derived from an IRE1 null (ΔIRE1) parental cell line. A 745 
representative data set out of three independent experiments is shown. Note the low 746 
XBP1::Turquoise intensity in stressed J-IRE1 rescued ΔIRE1 cells. 747 
(B) Two dimensional plots of mCherry and XBP1s::Turquoise signals of clones described in 748 
“A” transiently transfected with a plasmid encoding the SubA protease, which cleaves BiP at 749 
its interdomain linker and an mCherry fluorescent transfection marker. The inactive 750 
SubAS272A mutant was used as control. Representative data from nine biological repeats is 751 
shown. 752 
(C) Immunoblot (IB) of endogenous IRE1 and associated BiP recovered from the indicated 753 
cell lines by immunoprecipitation (IP) of IRE1. Quantification of the ratio of BiP to IRE1 754 
signals in three independent experiments is shown on the right (mean ± standard deviation, 755 
n.s.: not significant, *: p < 0.05, unpaired parametric Student’s t test). BiP in input cell lysates 756 
is provided as loading control. (Fig. 1 - source data 1) 757 
(D) Coomassie-stained SDS-PAGE gel of biotinylated IRE1LD (IRE1LD-bio) and a fusion of 758 
ERdj4’s J-domain to IRE1LD (J-IRE1LD-bio, as in “A”) and BiP, both recovered on a 759 
streptavidin matrix from samples constituted as indicated. Protein concentrations were 5 µM 760 
IRE1LD-bio variants, 30 µM BiP, 8 µM ERdj4, and 2 mM ATP. Proteins were eluted in SDS 761 
sample buffer. A representative data set out of three independent experiments is shown. 762 
(E) Time-dependent change in donor fluorescence of the indicated IRE1LD FRET pair 763 
incubated at t = 0 with the components shown to the right. IRE1LD proteins were either 764 
labelled with the donor molecule Oregon green 488 (OG) or the acceptor molecule TAMRA 765 
(TMR). Protein concentrations were 0.2 µM IRE1LD FRET pair, 30 µM BiP, 2.5 µM ERdj4 766 
and 2 mM ATP. A representative graph of three independent experiments is shown (Fig. 1 - 767 
source data 2). 768 
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Figure 1, supplement 1: Modification of the endogenous Ern1 locus to introduce 770 
IRE1LD variants. 771 
(A) Schematic description of the homologous recombination platform for creating 772 
IRE1-encoding alleles at the endogenous Ern1 locus (ΔIRE1, Kono et al., 2017). 773 
Cas9-CRISPR guides generated a large in-frame deletion between exons 2 and 11 in the 774 
endogenous Ern1 locus. In the resultant Ern1 null cell line (ΔLD15) the locus can be targeted 775 
with a unique Cas9-CRISPR guide and appropriate repair templates containing an intron-776 
free minigene consisting of exons 2-11 to generate IRE1LD variants stably expressed from 777 
the endogenous locus by homology-directed repair (HDR). 778 
(B) Scheme of IRE1 variants: wild-type IRE1 (wt) and chimeric J-domain IRE1 fusion 779 
proteins expressed from the endogenous Ern1 locus to probe the effect of BiP binding to 780 
IRE1 activity in cells. The J-domain (or QPD mutant) of ERdj4 was fused N-terminally to 781 
IRE1LD, whereby ERdj4’s glycine-phenylalanine-rich (G/F) region was included as a flexible 782 
linker between both domains.  783 
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Figure 2: Binding of MPZ-N peptide to IRE1LD does not promote IRE1LD dimerisation. 784 
(A) Size-exclusion chromatography (SEC) elution profiles of TAMRA (TMR)-labelled 785 
wild-type IRE1LD at the indicated concentrations in presence and absence of MPZ-N peptide. 786 
TMR fluorescence is plotted against elution time (see: Fig. 2 - source data 1). 787 
(B) SEC elution profiles (as in “A”), but with protein absorbance at 280 nm (A280) plotted 788 
against elution time. The inset is a zoom into the segment of the chromatogram 789 
encompassing the IRE1LD proteins, whose absorbance is dwarfed by the peak of free 790 
peptide (eluting at ~24 minutes). The heterogenous peaks eluting between 15-20 minutes in 791 
the sample loaded with 1 mM MPZ-N peptide, likely reflected peptide oligomerisation (see: 792 
Fig. 2 - source data 1). 793 
(C) Cartoon representation of the IRE1LD dimer (PDB: 2HZ6) is shown on the left with 794 
coloured secondary structures (cyan for helices, red for sheets and magenta for loops). The 795 
Gln105 side chain is shown as sticks, a closer view of which is shown on the top right. The 796 
bottom right panel shows a similar view of the Gln105Cys mutant (crystallised here), which 797 
forms a disulphide bond, covered with clear electron density (black mesh represents the 798 
2mFo − DFc map, contoured at 1.0 σ, including density within 2 Å of the cysteine residues). 799 
(D) Anisotropy of FAM labelled MPZ-N peptide (100 nM) in presence of increasing 800 
concentrations of either wild-type IRE1LD or disulphide-linked dimeric IRE1Q105C SS. Shown 801 
are data from three independent experiments (mean ± SD). Curve fitting was performed in 802 
Prism GraphPad 7.0 using equation 2 in methods (see: Fig. 2 - source data 2). 803 
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Figure 2, supplement 1: Biochemical properties of disulphide-linked dimeric 805 
IRE1LD Q105C SS and monomeric variants used to study MPZ-N’s interaction with 806 
IRE1LD. 807 
(A) Size-exclusion chromatography (SEC) elution profiles of wild-type (wt) and monomeric 808 
IRE1LD W125A and IRE1LD P108A proteins at the indicated concentrations. Protein absorbance at 809 
280 nm (A280) is plotted against elution time. Note the delayed peak elution times of the 810 
IRE1LD monomeric variants. The observation that IRE1LD wt and IRE1LD W125A variants eluted 811 
in a single peak yet shifting to later elution times with decreasing protein concentrations 812 
suggests that these proteins existed in a monomer-dimer exchange regime that is faster 813 
than the time scale of SEC. By contrast, IRE1LD P108A was monomeric at all tested 814 
concentrations. 815 
(B) Cartoon representation of the IRE1LD dimer interface with protomers in light and dark 816 
grey (PDB: 2HZ6). Residues that were mutated to create the monomeric variants 817 
IRE1LD W125A and IRE1LD P108A are located in close proximity to the dimer interface and are 818 
shown in orange or pink sticks, respectively.  819 
(C) Coomassie stained non-reducing SDS-PAGE gel of wt IRE1LD and disulphide-linked 820 
IRE1LD Q105C SS. 821 
(D) Scatter plot of the melting temperature (Tm) of the indicated IRE1
LD proteins (at 5 µM) in 822 
absence or presence of the reducing agent TCEP or increasing concentrations of MPZ-N 823 
peptide measured by differential scanning fluorimetry (DSF) is depicted on the left. Shown 824 
are the data points of three independent experiments [mean ± standard deviation (SD)] with 825 
monomeric IRE1LD W125A and IRE1LD P108A, wt IRE1LD and a disulphide-linked dimeric 826 
IRE1LD Q105C SS or its reduced version IRE1LD Q105C SH. Statistical analysis for indicated 827 
conditions was performed in comparison to wt IRE1LD (***: p < 0.001, ****: p < 0.0001, 828 
ordinary one-way ANOVA). Traces of melt curves with their negative first derivatives from a 829 
representative experiment are shown on the right (peak fluorescence was normalised). 830 
(E) Overlay of the cartoon representation of IRE1LD (PDB: 2HZ6) and the disulphide-linked 831 
IRE1LD Q105C SS. The root-mean squared deviation (RMSD) over 227 Cα atoms is 0.46 Å.  832 
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Figure 2, supplement 2: Implications of the distance constraint arising from the 834 
paramagnetic relaxation enhancement (PRE) experiments with IRE1LD and an MPZ-835 
proxyl-labelled peptide (Karagoz et al., 2017) to the possible modes of peptide 836 
binding. 837 
(A) Cartoon representation of the IRE1LD dimer with protomers in light and dark grey (PDB: 838 
2HZ6). The two helices flanking the MHC-like groove are coloured in blue. The isoleucines 839 
(Ile) whose peaks were suppressed or broadened upon introduction of the spin-labeled MPZ 840 
peptide are highlighted in red and yellow, respectively (from figure 5 in Karagoz et al., 2017, 841 
doi.org/10.7554/eLife.30700.016). The incorporated spin label causes broadening of Ile 842 
peaks in a range of 10 to 25 Å or entirely erases them within distances of <10 Å (Gottstein et 843 
al., 2012). Therefore, the broadening of peaks observed in the NMR spectra of IRE1LD 844 
serves as a distance constraint, positioning the labelled residue of the MPZ peptide within 10 845 
Å of Ile186 (in red). The blue mesh of 10 Å diameter centred on Ile186 depicts the distance 846 
constrain on the proxyl-labelled Cys5 of the MPZ peptide (LIRYCWLRRQAALQRRISAME). 847 
(B). As in “A”, but with two extra spheres centred at Ile186 with diameters of 26 Å (yellow 848 
meshes) and 58 Å (grey meshes) to show the possible location of the MPZ peptide in either 849 
helical or extended conformation, respectively. Also shown is the 8-residues-long peptide 850 
(magenta) present in the yeast IRE1LD crystal structure (Credle et al., 2005, PDB: 2BE1, 851 
superimposed onto the human model) and a superimposed peptide (cyan) found in the 852 
PERKLD structure (Wang et al., 2018, PDB: 5V1D). Note: There are 16 residues between 853 
Cys5 and the C-terminus of the MPZ peptide. If extended, the peptide is free to sample a 854 
sphere with a radius of ~48 Å from Cys5. Given that the PRE experiments place Cys5 of the 855 
peptide anywhere within 10 Å of IRE1LD Ile186, if extended, the peptide is free to explore the 856 
entire space encompassed by the grey mesh. Even if constrained to assume a compressed 857 
helical conformation, the peptide could be found anywhere within the yellow mesh. The 858 
numerous perturbations to the NMR spectrum arising from the presence of unlabelled 859 
peptide may reflect either the consequences of a peptide-IRE1LD interaction or an induced 860 
conformational change in the IRE1LD (as noted by Karagoz et al., 2017). Therefore, they do 861 
not constrain the location of the peptide. Constraint is provided by the PRE experiments, 862 
noted above, but these are not incompatible with the peptide binding outside the MHC-like 863 
groove. 864 
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Figure 3: Identification of flexible regions in IRE1LD that are important for the 866 
regulation of IRE1 activity in cells. 867 
(A) Left panel shows a bar diagram of the percentage of amide hydrogen exchange (%ex) of 868 
the indicated by IRE1LD segments after 30 and 300 seconds incubation in D2O. The amino 869 
acids (aa) covered by the peptic fragments are indicated on the left. Exchange was 870 
corrected for back exchange using a fully deuterated IRE1LD preparation. Protein 871 
concentration was 5 µM. Shown are the data of three independent experiments (mean ± 872 
standard deviation). Right panel shows a cartoon of the IRE1LD dimer (PDB: 2HZ6) with the 873 
left protomer coloured according to %ex at 30 seconds (areas with no sequence coverage 874 
are uncoloured). The location of the putative loop (residues 308-357) and the tail (residues 875 
390-444) are schematically represented as dotted lines (see: Fig. 3 -source data 1) 876 
(B) Schematic description of a directed in vivo CRISPR-Cas9 mutagenesis strategy to probe 877 
regions of IRE1LD for their relevance to regulating activity in CHO-K1 cells. Cas9 guides (red 878 
triangles) targeted sites across the Ern1 genomic locus encoding the protein’s region of 879 
interest. Transfection of individual or pairs of guides resulted in a collection of mutations 880 
(insertions and deletions, depicted as blue and red lines). Cell harbouring rare de-repressing 881 
mutations of IRE1 (blue) were selected by fluorescence-activated cell sorting (FACS) gated 882 
on XBP1s::Turquoise high and CHOP::GFP low signals. The resultant clones were isolated 883 
and genotyped. 884 
(C) Left panel is a histogram of XBP1s::Turquoise intensity of CHO-K1 dual UPR reporter 885 
cell populations transfected with guide-Cas9 encoding plasmids targeting a putative 886 
unstructured loop (aa 308-357) within IRE1LD (identified in “A”). XBP1s::Turquoise bright 887 
cells within population 0 were collected by FACS (FACS1) yielding population 1, followed by 888 
a second round of enrichment for bright cells (FACS2 yielding population 2). Population 2 889 
was treated with the IRE1 inhibitor 4µ8c to select against clones exhibiting IRE1-890 
independent reporter activity. The final population was genotypically analysed 891 
(representative sequences are shown on the right). Frameshift mutations are coloured in 892 
blue and Cas9 cut sites are indicated below. 893 
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Figure 3, supplement 1: IRE1’s tail region is involved in maintaining the repressed 895 
state of IRE1 in vivo. 896 
(A) Schematic representation of IRE1. The signal peptide (SP), luminal domain (LD), 897 
comprised of a structured core (CLD) and an unstructured tail, the transmembrane (TM) 898 
domain and the cytosolic effector domains are indicated with their corresponding amino acid 899 
(aa) resides below. 900 
(B) Representative sequences of clones that were selected as described in Fig. 3C after 901 
transfection of cells with guide-Cas9 encoding plasmids targeting IRE1’s tail (residues 902 
368-444). Frameshift mutations are coloured in blue and Cas9 cut sites are indicated by 903 
arrowheads below. 904 
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Figure 4: Cells expressing IRE1LD deletion variants exhibit a de-repressed IRE1 906 
phenotype that correlates with less BiP bound to IRE1. 907 
(A) Bar diagram of median XBP1::Turquoise and CHOP::GFP signals from untreated and 908 
tunicamycin (Tm)-treated CHO-K1 dual UPR reporter cells with Ern1 alleles encoding 909 
wild-type (wt) or the indicated deletion variants of IRE1 (∆loop, missing residues 313-338, 910 
∆tail, missing residues 391-444, or ∆∆, missing both). Data from four independent 911 
experiments is shown [mean ± standard deviation (SD), **: p < 0.01, ****: p < 0.0001, one-912 
way ANOVA with Sidak’s multiple comparison test] (Fig. 4 - source data 1). 913 
(B) Representative immunoblot (IB) of endogenously-expressed wt or the IRE1 ∆∆ deletion 914 
mutant (see “A”) and associated BiP recovered by immunoprecipitation (IP) of IRE1. BiP in 915 
input cell lysates is provided as a loading control. Quantification of the ratio of BiP to IRE1 916 
signals after IP of three independent experiments is shown below (mean ± SD, *: p < 0.05, 917 
ratio paired parametric Student’s t test) (see: Fig. 4 - source data 2) 918 
(C) Left panel shows a representative immunoblot of the indicated IRE1 variants with 919 
glutathione S-transferase (GST) replacing the cytosolic domain. The proteins were 920 
introduced into CHO-K1 cells by transient transfection, and the associated endogenous BiP 921 
recovered by glutathione pull down. BiP in input cell lysates is provided as a loading control. 922 
Quantification of the ratio of BiP to IRE1 signals in the IP of three independent experiments 923 
is shown to the right (mean ± SD, *: p < 0.05, **: p < 0.01, ***: p < 0.001, one-way ANOVA 924 
with Sidak’s multiple comparison test). 925 
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Figure 4, supplement 1: Single or double deletion of a flexible loop and the tail within 927 
IRE1LD de-repressed IRE1 basal activity.  928 
(A) Two dimensional contour plots of untreated and tunicamycin (Tm)-treated CHO-K1 929 
CHOP::GFP and XBP1s::Turquoise dual UPR reporter cells expressing the indicated alleles 930 
(as in Fig. 4A) analysed by flow cytometry. The measurements were performed after 931 
transient transfection of Cas9-CRISPR guides together with the respective repair templates 932 
yielding populations that had and had not undergone homologous recombination (“Analysis 933 
of mixed population”). Representative data from four independent experiments is shown. 934 
(B) Contour plot (as in “A”) of clonal cell lines expressing the same alleles used in the 935 
experiment shown in Fig. 4B. Representative data from three biological repeats is shown. 936 
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Figure 5: Impaired BiP binding and monomerisation of IRE1LD ΔΔ in vitro. 938 
(A) Left panel shows Bio-Layer Interferometry (BLI)-derived association (assoc.) and 939 
dissociation (dissoc.) traces of streptavidin sensors loaded with the indicated biotinylated 940 
ligands [a fusion of ERdj4’s J-domain to IRE1LD wild-type (wt) or ∆∆, as in Fig. 1D] and 941 
exposed sequentially to the indicated solutions of analyte (containing wt BiP or the client-942 
binding mutant BiPV461F). A representative experiment of three independent repetitions is 943 
shown. The traces were subtracted against a background derived from a BLI sensor with no 944 
ligand and the BLI signals (displacement) were set to zero after the first washing step. 945 
Quantification of the dissociation rate constants koff after association in presence of 0.15 µM 946 
BiP and 2 mM ATP are shown to the right. Traces were fitted to a two-phase dissociation 947 
function in Prism GraphPad 7.0. Shown are the mean ± standard deviation (SD) of three 948 
independent repetitions (n.s.: not significant, unpaired parametric Student’s t test).  949 
(B) Coomassie-stained SDS-PAGE gel of biotinylated wt IRE1LD (IRE1LD-bio), double 950 
deleted IRE1LD ∆∆ (IRE1LD ∆∆-bio) and BiP, recovered on a streptavidin matrix from samples 951 
constituted as indicated. 2 mM ATP was used during wash steps of the matrix when 952 
indicated. A representative data set is shown. Quantification of the ratio of BiP to IRE1 953 
signals in the relevant samples after pull down from three independent experiments is shown 954 
on the right (mean ± SD, *: p < 0.05, **: p < 0.01, one-way ANOVA with Sidak’s multiple 955 
comparison test). 956 
(C) Time-dependent change in donor fluorescence of the indicated IRE1LD FRET pair 957 
incubated at t = 0 with the components shown to the right. The asterisks mark samples set 958 
up with a mock FRET sensor lacking the IRE1LD donor-labelled molecule. Protein 959 
concentrations were 0.2 µM FRET pair, 30 µM BiP, 2.5 µM full-length ERdj4 (or its isolated 960 
J-domain) and 2 mM ATP. A representative experiment of three independent repetitions is 961 
shown. When indicated, the data points were fitted to a one-phase association function in 962 
Prism GraphPad 7.0; the initial velocity represents the slope of the curve at time point zero 963 
(mean ± SD, ***: p < 0.001, unpaired parametric Student’s t test) (see: Fig. 5 - source data 964 
1). 965 
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Figure 5, supplement 1: The ∆∆ deletion does not affect the stability of the IRE1LD 967 
dimer. 968 
(A) Bio-Layer Interferometry (BLI)-derived association (assoc.) and dissociation (dissoc.) 969 
traces of streptavidin sensors loaded with the indicated biotinylated ligands [wild-type (wt) or 970 
IRE1LD ∆∆] and exposed sequentially to the indicated solutions of analyte. 2 µM BiP, 6.8 µM 971 
full-length ERdj4, or isolated J-domain and 2 mM ATP. A representative experiment of three 972 
independent repetitions is shown (processed as in Fig. 5A). 973 
(B) As in Fig. 5A but comparing the monomeric J-IRE1LD P108A and the disulphide-linked 974 
J-IRE1LD Q105C SS proteins as ligands on the sensor. A representative experiment of three 975 
independent repetitions is shown. 976 
(C) Size-exclusion chromatography (SEC) elution profiles of TAMRA (TMR)-labelled wt and 977 
IRE1LD ΔΔ proteins at the indicated concentrations. TMR fluorescence is plotted against 978 
elution time [note: fluorescent labelling was used to detect a signal at the low protein 979 
concentration (conc.) required to generate a pool of monomeric IRE1LD] (see: Fig. 5 - source 980 
data 2) 981 
(D) Plot of peak elution time points derived from “C” against the protein concentration on a 982 
logarithmic scale for IRE1LD and IRE1LD ΔΔ. Curve fitting was performed in Prism GraphPad 983 
7.0 using a sigmoidal function and calculated K1/2 max values are displayed underneath the 984 
curves. 985 
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Figure 6: BiP-mediated monomerisation of IRE1LD ∆∆ assessed by hydrogen 987 
exchange mass spectrometry (HX-MS). 988 
(A) Difference plot of deuteron incorporation into comparing wild-type (wt) IRE1LD with the 989 
monomeric mutants IRE1LD W125A (orange trace) or IRE1LD P108A (pink trace) after 30 seconds 990 
incubation in D2O [see Table 2 for the amino acid (aa) sequence of the individual segments]. 991 
Protein concentration was 5 µM. Shown are data from three independent experiments [mean 992 
± standard deviation (SD)]. Boxes 1 and 2 highlight regions of greater hydrogen exchange 993 
(HX) in the monomeric mutants compared to wt IRE1LD that were analysed in presence of 994 
chaperones in “C” (see Fig. 6 - source data 1).  995 
(B) Cartoon representation of the IRE1LD dimer (PDB: 2HZ6) coloured according to the 996 
difference of deuteron incorporation between wt and IRE1LD P108A after 30 seconds of 997 
incubation in D2O (from “A”).  998 
(C) Difference plot of the deuteron incorporation between the untreated sample and samples 999 
exposed to the indicated additives. The data for the same peptic peptides from wt IRE1LD 1000 
and the IRE1LD ΔΔ mutant are displayed separately. Protein concentrations were 5 µM IRE1LD 1001 
(wt or ∆∆ mutant), 30 µM BiP (wt or V461F mutant), 6 µM ERdj4 (wt or QPD mutant) and 1002 
2 mM ATP. Shown are the means ± SD of three data sets acquired after 30 seconds 1003 
incubation in D2O (the corresponding 300 seconds data set is presented in Fig. 6, 1004 
supplements 1A and 1C) (see Fig 6 - source data 2). 1005 
  1006 
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Figure 6, supplement 1: HX-MS evidence for impaired BiP- and ERdj4-driven 1007 
monomerisation of IRE1LD ΔΔ. 1008 
(A) Difference plot of deuteron incorporation into the indicated peptic peptides of wild-type 1009 
(wt) versus IRE1LD W125A or wt versus IRE1LD P108A after 300 seconds incubation in D2O (as in 1010 
Fig. 6A) (see Fig. 6 - source data 1). 1011 
(B) Overlay of representative spectra showing the isotope cluster of peptic fragment 1012 
779.0873+ (residues 86-106) from wt or IRE1LD ∆∆, untreated (black) or exposed to BiP, ERdj4 1013 
and ATP (red) after 300 seconds incubation in D2O. Peaks arising from overlapping BiP 1014 
peptides are coloured in grey. Note the stronger shift of the peaks towards higher m/z values 1015 
(indicating an increased deuteron incorporation) in case of wt IRE1LD in presence of BiP, 1016 
ERdj4 and ATP. 1017 
(C) Difference plot of the deuteron incorporation between the untreated sample and samples 1018 
exposed to the indicated additives. The data for the same peptic peptides from wt and the 1019 
IRE1LD ΔΔ mutant are displayed separately (as in Fig. 6C, but after 300 seconds incubation in 1020 
D2O) (see Fig. 6 - source data 2) 1021 
(D) Difference plot of deuteron incorporation into the indicated peptic peptides of wt versus 1022 
IRE1LD ∆∆ mutant after 30 or 300 seconds incubation in D2O as in Fig. 6A (in absence of 1023 
chaperones). Regions deleted in IRE1LD ΔΔ are excluded from the difference plot. 1024 
1025 
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Figure 7: Analysis of bimodally-distributed isotope clusters of IRE1LD peptic peptides 1026 
reveals active destabilisation of the IRE1LD dimer by BiP. 1027 
(A) Intensity distributions of the isotope clusters of peptide 655.273+ (residues 297-302) from 1028 
IRE1LD, untreated or exposed to BiP, ERDj4 and ATP (30 minutes at 30°C) following 1029 
different incubation times in D2O, as indicated. Curves are fits of the sum of two Gaussian 1030 
distributions (Prism GraphPad 7.0, see equation 4 in methods). A representative plot of three 1031 
independent experiments is shown. (see: Fig. 7-source 1) 1032 
(B) Plot of time-dependent change in the fractional contribution of high mass species to the 1033 
isotope clusters of peptide 655.273+ (from “A”) calculated as described in Fig. 7, 1034 
supplements 1A and 1B. Shown are data points from three independent samples of IRE1LD 1035 
in presence and absence of BiP, ERdj4 and ATP. The curves were fitted to a one-phase 1036 
association model in Prism GraphPad 7.0. Data for a second informative peptide is shown in 1037 
Fig. 7, supplement 1C. 1038 
(C) Bar diagram of the transition rate constant ktrans extracted by analysis of bimodal 1039 
distributions in the isotope clusters of peptic fragments 636.3802+ and 655.273+ from IRE1LD 1040 
in presence and absence of BiP, ERdj4 and ATP (from Fig. 7B and Fig. 7,supplement 1C). 1041 
All the data points from three independent experiments are shown and the mean ± standard 1042 
deviation (**: p < 0.01, ****: p < 0.0001, one-way ANOVA with Sidak’s multiple comparison 1043 
test). 1044 
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Figure 7, supplement 1: Analysis of the bimodal distributions of the isotope clusters 1046 
detected by HX-MS. 1047 
(A) Shown are original spectra of peptic peptide 655.273+ (residues 297-302) from 1048 
monomeric IRE1LD P108A (left panel) or wild-type IRE1LD (right panel) at the indicated time 1049 
point of incubation in D2O. The contribution of the low (blue) and high (red) exchanging 1050 
populations to the peaks was extracted by fitting the data to a two Gaussian distribution 1051 
model (equation 4). Unexchanged and 100% exchanged spectra are provided as references.  1052 
(B) Plot of the two individual Gaussian distributions of the high (h) and low (l) exchanging 1053 
populations deconvoluted computationally in Prism GraphPad 7.0 from the composite data 1054 
set shown in Fig. 7A for each time point of incubation in D2O.  1055 
(C) Plot of time-dependent change in the fractional contribution of high mass species to the 1056 
isotope clusters of peptic peptide 636.3802+ (residues 96-106). Shown are data points from 1057 
three independent samples of IRE1LD in presence and absence of BiP, ERdj4 and ATP (as 1058 
in Fig. 7B). The curves were fitted to a one-phase association model in Prism GraphPad 7.0. 1059 
  1060 
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Figure 8: Cartoon depicting features of BiP-mediated regulation of IRE1 activity. 1061 
In stressed cells unfolded proteins compete for BiP, exposing IRE1LD to a default dimeric 1062 
active state, specified by the kinetics of the monomer-dimer equilibrium (left panel). In 1063 
compensated cells BiP (assisted by ERdj4 and possibly other J-domain proteins, not shown) 1064 
binds flexible regions of IRE1LD. Engagement of these regions in the IRE1LD dimer may favor 1065 
active dimer disassembly by entropic pulling or allosterically induced conformational 1066 
changes (right panel). BiP binding to the same flexible regions of the IRE1LD monomer, may 1067 
inactivate IRE1 by disfavoring re-dimerisation (right panel). The dynamic nature of BiP 1068 
binding, which entails cycles for ATP hydrolysis-driven client engagement and nucleotide 1069 
exchange-mediated release, ensures that IRE1 activity is kinetically coupled to the balance 1070 
between unfolded protein load and folding capacity of the cell.  1071 
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Tables 1072 
Table 1: Data Collection and refinement statistics of IRE1LDQ105C SS. 1073 
* Values in parentheses are for highest-resolution shell. 1074 
† 100th percentile is the best among structures of comparable resolutions. 0th percentile is 1075 
the worst.  1076 
  1077 
Data collection 
Synchrotron stations DLS I04-1 
Space group P6522 
a,b,c; Å 182.77, 182.77, 68.45 
α, β, γ;  90.00, 90.00, 120.00 
Resolution, Å 91.39-3.55 (3.89-3.55)* 
R
merge
 0.180 (2.242)* 
<I/σ(I)> 11.7 (1.5)* 
CC1/2 1.000 (0.797)* 
No. of unique reflections 8590 (1996)* 
Completeness, % 100.0 (100.0)* 
Redundancy 19.3 (19.9)* 
Refinement 
R
work
/R
free
 0.323/0.332 
No. of atoms (non H) 1784 
Average B-factors 127 
RMS Bond lengths Å 0.003 
RMS Bond angles,  0.606 
Ramachandran favoured region, % 95.85 
Ramachandran outliers, % 0 
MolProbity score† 1.51 (100th) 
PDB code 6HSC 
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Table 2: List of IRE1LD peptic peptides analysed by hydrogen-1H/2H-exchange mass 1078 
spectrometry (HX-MS) containing the respective m/z values, charge (z) and sequence of 1079 
each peptide. Note that the N-terminal amide hydrogen of each peptic fragment exchanges 1080 
too fast to be detectable with this method. Hence, the N-terminal residue was excluded from 1081 
the data analysis. 1082 
Residues m/z z Sequence 
24-36  631.345 2 STSTVTLPETLL  
37-45  938.478 1 FVSTLDGSL  
46-59  396.730 4 HAVSKRTGSIKWTL  
77-85  927.435 1 LPDPNDGSL  
86-106  779.087 3 YTLGSKNNEGLTKLPFTIPEL  
96-106  636.380 2 LTKLPFTIPEL  
107-119 1316.680 1 VQASPSRSSDGIL  
120-128 390.199 3 YMGKKQDIW  
130-134  735.424 1 YVIDLL  
134-145  631.832 2 LTGEKQQTLSSA  
147-157 1090.563 1 ADSLSPSTSLL  
157-168  730.874 2 LYLGRTEYTITM  
168-175  522.242 2 MYDTKTRE  
176-183  535.772 2 LRWNATYF  
186-195 1031.447 1 AASLPEDDVD  
196-208  727.837 2 YKMSHFVSNGDGL  
209-221  703.343 2 VVTVDSESGDVLW  
221-232  697.856 2 WIQNYASPVVAF  
233-240 1050.537 1 YVWQREGL  
241-248 332.864 3 RKVMHINV  
253-258  406.735 2 LRYLTF  
280-287 444.28 2 KSKLTPTL  
288-296 1017.525 1 YVGKYSTSL  
297-302 655.273 1 YASPSM  
303-316 474.268 3 VHEGVAVVPRGSTL  
317-335 956.978 2 PLLEGPQTDGVTIGDKGES  
343-360  534.307 4 VKFDPGLKSKNKLNYLRN  
365-378  503.588 3 IGHHETPLSASTKM  
379-404  516.606 6 LERFPNNLPKHRENVIPADSEKKSFE  
410-424  810.376 2 VDQTSENAPTTVSRD  
410-443  727.149 5 VDQTSENAPTTVSRDVEEKPAHAPARPEAPVDSM  
 1083 
  1084 
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Methods 1091 
Table 3: Key resource table 1092 
Reagent type 
(species) or 
resource 
Designation 
Source or 
reference 
Identifie
rs 
Additional information 
strain, strain 
background 
(Escherichia 
coli) 
BL21 C3013 E. coli  NEB 
Cat no: 
C3013I 
  
strain, strain 
background 
(Escherichia 
coli) 
Origami B(DE3) E. coli  
Novagen/M
ERCK 
Cat no: 
70837 
  
antibody 
Anti-mouse IRE1α serum 
(rabbit polyclonal) 
Bertolotti et 
al., 2000 
NY200 used at 1/1000 
antibody 
anti-hamster BiP 
(chicken polyclonal) 
Avezov et 
al., 2013 
Anti-BiP used at 1/1000 
antibody Anti-GST (polyclonal 
rabbit) 
Ron and 
Habener, 
1992 
Anti-
CHOP 
used at 1/1000 
Cell line, 
(Cricetulus 
griseus) 
Clone S21 a derivative of 
RRID: CVCL_0214 
Sekine et 
al., 2016 
CHO-K1 
S21 
CHO CHOP::GFP, 
XBP1s::Turquoise dual UPR 
reporter cell line 
Cell line, 
(Cricetulus 
griseus) 
CHO-K1 S21 
CHOP::GFP, 
XBP1s::Turquoise ∆LD 
15 
Kono et al., 
2017 
∆IRE1 
CHO CHOP::GFP, 
XBP1s::Turquoise dual UPR 
reporter, Ern1 null cell line 
Cell line, 
(Cricetulus 
griseus) 
CHO-K1 S21 
CHOP::GFP, 
XBP1s::Turquoise IRE1 
wild-type 
This paper 
IRE1 
wild-
type 
CHO CHOP::GFP, 
XBP1s::Turquoise dual UPR 
reporter, Ern1 null cell line 
reconstituted with IRE1 wild-
type  
Cell line, 
(Cricetulus 
griseus) 
CHO-K1 S21 
CHOP::GFP, 
XBP1s::Turquoise IRE1 
∆∆  
This paper 
IRE1 ∆∆  
CHO CHOP::GFP, 
XBP1s::Turquoise dual UPR 
reporter, Ern1 null cell line 
reconstituted with IRE1 ∆∆ 
(missing residues 313-338 
and 391-444) 
Peptide, 
recombinant 
protein 
MPZ-N Karagoz et 
al., 2017 
MPZ-N 
12-mer peptide (MPZ-N) 
derived from myelin protein 
zero 
Peptide, 
recombinant 
protein 
FAM-MPZ-N Karagoz et 
al., 2017 
FAM-
MPZ-N 
FAM labelled 12-mer peptide 
(MPZ-N) derived from myelin 
protein zero 
Software, 
algorithm 
Prism GraphPad     
Software, 
algorithm 
FlowJo,LLC,        
Software, 
algorithm Data Analysis 4.1 
Bruker     
Chemical 
compound, 
drug Tunicamycin Melford 
Cat no: 
T2250 
  
Chemical 
compound, 
drug 
2-Deoxyglucose Sigma 
Cat no: 
D6134 
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Chemical 
compound, 
drug 
4μ8c 
Tocris 
Bioscience 
Cat no: 
4479 
  
Chemical 
compound, 
drug 
Digitonin Calbiochem 
Cat no: 
300410 
  
Chemical 
compound, 
drug 
Biotin-NHS ester Sigma 
Cat no: 
H1759 
  
Chemical 
compound, 
drug 
Protease inhibitors 
Sigma 
Aldrich 
(MERCK) 
S8830   
Chemical 
compound, 
drug 
Oregon Green-
iodoacetic acid 
ThermoFis
her 
Cat no: 
O6010 
  
Chemical 
compound, 
drug 
TAMRA-maleimide Sigma 
Cat no: 
94506 
  
Chemical 
compound, 
drug Phosphocreatine 
Sigma 
Cat no: 
106217
14001 
  
Chemical 
compound, 
drug 
Creatine kinase Sigma 
Cat no: 
C3755 
  
Recombinant 
DNA reagent 
haBiP_27-654_pQE10 
(plasmid) 
Petrova et 
al., 2008 UK173 
N-terminally His6-tagged 
hamster BiP 
Recombinant 
DNA reagent 
haBiP_27-
654_V461F_pQE10 
(plasmid) 
Petrova et 
al., 2008 UK182 
N-terminally His6-tagged 
hamster BiP V461F 
Recombinant 
DNA reagent 
haBiP_27-
654_ADDA_pQE10 
(plasmid) 
Preissler et 
al., 2015a UK984 
N-terminally His6-tagged 
hamster BiP ADDA 
Recombinant 
DNA reagent 
H6_Ulp1_pET28b 
(plasmid) 
This study UK1249 H6-tagged Ulp1 
Recombinant 
DNA reagent 
pCEFL_mCherry_3XFLA
G_C (plasmid) 
Sekine et 
al., 2015 
UK1314 
pCEFL with 3XFLAG_C 
tagged from mCherry-tagged 
plasmid 
Recombinant 
DNA reagent 
BPPTSP_SubA_22-
347_3XFLAG_KDEL_pU
C57_Acc65I_based_pC
EFL_mCherry (plasmid) 
This study UK1452 
3xFLAG-tagged SubA with 
KDEL on mCherry-tagged 
plasmid 
Recombinant 
DNA reagent 
BPPTSP_SubA_22-
347_S272A_3XFLAG_K
DEL_pUC57_Acc65I_ba
sed_pCEFL_mCherry 
(plasmid) 
This study UK1459 
3xFLAG-tagged SubA
S272A
 
with KDEL mCherry-tagged 
plasmid 
Recombinant 
DNA reagent 
hIRE1_19-
486_dC_GST_del3UTR 
_pCDNA3 (plasmid) 
Amin-
Wetzel et 
al., 2017 
UK1703 
C-GST-tagged cysteine-free 
human IRE1 
Recombinant 
DNA reagent 
CHO_IRE1_guideC15.1
_pSpCas9(BB)-2A-
mCherry (plasmid) 
Kono et al., 
2017 
UK1903 
Cas9 and guide targeting 
IRE1 in CHO-K1 ∆LD clone 
15 (mCherry-tagged) 
Recombinant 
DNA reagent 
CHO_IRE1_hIRE1-
LD_reptemp4_pCR-
Blunt2-TOPO (plasmid) 
Kono et al., 
2017 
UK1968 
Repair template for wild-type 
IRE1 reconstitution in CHO-
K1 cells 
Recombinant 
DNA reagent 
Smt3_cgERdj4_24-
222_pET-21a (plasmid) 
Amin-
Wetzel et 
al., 2017 
UK2012 
N-Smt3-tagged Chinese 
hamster ERdj4 24-222 
Recombinant Smt3_J4_domain_24- Amin- UK2041 N-Smt3-tagged Chinese 
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DNA reagent 90_pET-21a (plasmid) Wetzel et 
al., 2017 
hamster ERdj4 24-90 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD∆C_24_444 
(plasmid) 
This study UK2042 
N-His6-Smt3-tagged 
wild-type human IRE1
LD
 24-
444 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD∆C_24_444 Q105C 
(plasmid) 
Amin-
Wetzel et 
al., 2017 
UK2045 
N-His6-Smt3-tagged 
cysteine-free human 
IRE1
LD Q105C 
24-444 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD∆C_24_444 R234C 
(plasmid) 
Amin-
Wetzel et 
al., 2017 
UK2048 
N-His6-Smt3-tagged 
cysteine-free human IRE1
LD
 
24-444, R234C (FRET 
probe) 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD∆C_24_444 S112C 
(plasmid) 
Amin-
Wetzel et 
al., 2017 
UK2076 
N-His6-Smt3-tagged 
cysteine-free human IRE1
LD
 
24-444, S112C (FRET 
probe) 
Recombinant 
DNA reagent 
Smt3_cgERdj4_24-
222_GS6_MalE_pET21a 
(plasmid) 
Amin-
Wetzel et 
al., 2017 
UK2108 
N-Smt3-ERdj4-MBP Chinese 
hamster 24-222 
Recombinant 
DNA reagent 
Smt3_cgERdj4_24-
222_QPD_GS6_MalE_p
ET21a (plasmid) 
Amin-
Wetzel et 
al., 2017 
UK2119 
N-Smt3-ERdj4-MBP Chinese 
hamster residues 24-222 
H54Q 
Recombinant 
DNA reagent 
IRE1a_LD_∆C_24-
443_AviTag_H6_pET30
a (plasmid) 
This study UK2246 
C-Avi-His6-tagged cysteine-
free human IRE1
LD
 24-444 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD∆C_Q105C_24_390 
(plasmid) 
This study UK2304 
N-His6-Smt3-tagged 
cysteine-free human 
IRE1
LD Q105C 
24-390 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD_dC_24_390_∆313-
338_S112C (plasmid) 
This study UK2370 
N-His6-Smt3-tagged 
cysteine-free human 
IRE1
LD ∆∆ 
(313-338, 391-444) 
S112C, FRET probe 
Recombinant 
DNA reagent 
CHO_IRE1_hIRE1-
LD_d313-
338_reptemp4_pCR-
Blunt2-TOPO (plasmid) 
This study UK2384 
Repair template for IRE1 
∆loop (d313-338) 
reconstitution in CHO-K1 
cells 
Recombinant 
DNA reagent 
CHO_IRE1_hIRE1-
LD_d391-
444_reptemp4_pCR-
Blunt2-TOPO (plasmid) 
This study UK2385 
Repair template for IRE1 
∆tail (d391-444) 
reconstitution in CHO-K1 
cells 
Recombinant 
DNA reagent 
CHO_IRE1_hIRE1-
LD_d313-338_d391-
440_reptemp4_pCR-
Blunt2-TOPO (plasmid) 
This study UK2386 
Repair template for IRE1 ∆∆ 
(d313-338, 391-444) 
reconstitution in CHO-K1 
cells 
Recombinant 
DNA reagent 
hIRE1α_19-486_dC_ 
d313-338_d391-
440_GST_del3UTR 
_pCDNA3 (plasmid) 
This study 
UK2401 
C-GST-tagged cysteine-free 
human IRE1 ∆∆ (missing 
residues 313-338 and 391-
444) 
Recombinant 
DNA reagent 
hIRE1α_19-486_dC_ 
d313-
338_GST_del3UTR 
_pCDNA3 (plasmid) 
This study 
UK2404 
C-GST-tagged cysteine-free 
human IRE1 ∆loop (missing 
residues 313-338) 
Recombinant 
DNA reagent 
hIRE1α_19-486_dC_ 
d391-
440_GST_del3UTR 
_pCDNA3 (plasmid) 
This study 
UK2406 
C-GST-tagged cysteine-free 
human IRE1 ∆∆ (missing 
residues 391-444) 
Recombinant 
DNA reagent 
Met_ERdj4_24-
120_Ire1a_LD∆C_24-
443_AviTag_H6_pET30
This study UK2408 
C-Avi-His6-tagged cysteine-
free chimeric J-ERdj4 human 
IRE1
LD
 24-444 protein 
IRE1 Monomerisation (V41.1) 
 42 
a (plasmid) 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD_dC_24_444_P108A 
(plasmid) 
This study UK2410 
N-His6-Smt3-tagged 
cysteine-free human 
IRE1
LD P108A 
monomeric 
mutant 24-444 
Recombinant 
DNA reagent 
pET22b_H7_Smt3_Ire1a
_LD_dC_24_444_W125
A (plasmid) 
This study UK2411 
N-His6-Smt3-tagged 
cysteine-free human 
IRE1
LD W125A 
monomeric 
mutant 24-444 
Recombinant 
DNA reagent 
Met_ERdj4_24-
120_Ire1a_LD∆C_24-
443_S112C_AviTag_H6
_pET30a (plasmid) 
This study UK2412 
C-Avi-His6-tagged cysteine-
free chimeric J-ERdj4 human 
IRE1
LD
 24-444 protein, 
S112C (FRET probe) 
Recombinant 
DNA reagent 
J4_WT_IRE1_LD_CHO
RepairTemplate 
(plasmid) 
This study UK2425 
Repair template for chimeric 
J-IRE1 reconstitution in 
CHO-K1 cells 
Recombinant 
DNA reagent 
J4_QPD_IRE1_LD_CHO
RepairTemplate_V1 
(plasmid) 
This study UK2426 
Repair template for chimeric 
J
QPD
-IRE1 reconstitution in 
CHO-K1 cells 
Recombinant 
DNA reagent 
Met_ERdJ4_24-
120_Ire1a_LD∆C_24-
443_P108A_AviTag_H6
_pET30a (plasmid) 
This study 
UK2428 
C-Avi-His6-tagged cysteine-
free chimeric J-ERdj4 human 
IRE1
LD
 24-444 protein 
containing monomerising 
mutation P108A 
Recombinant 
DNA reagent 
Met_ErdJ4_24-
120_IRE1a_LD∆C_24-
390_∆313-
338_AviTag_H6_pET30
a (plasmid) 
This study UK2458 
C-Avi-His6-tagged cysteine-
free chimeric J-ERdj4 human 
IRE1
LD ∆∆
 protein (313-338, 
391-444) 
Recombinant 
DNA reagent 
IRE1a_LD∆C_24-
390_∆313-
338_AviTag_H6_pET30
a (plasmid) 
This study UK2459 
C-Avi-His6-tagged cysteine-
free human IRE1
LD ∆∆ 
(d313-
338, 391-444) 
Recombinant 
DNA reagent 
Met_ERdJ4_24-
120_Ire1a_LD∆C_24-
443_Q105C_AviTag_H6
_pET30a (plasmid) 
This study 
UK2558 
C-Avi-His6-tagged cysteine-
free chimeric J-ERdj4 human 
IRE1
LD
 24-444 protein 
containing mutation Q105C 
 1093 
Mammalian cell culture 1094 
The parental strains for the CRISPR-Cas9-mediated homologous recombination approaches 1095 
were the previously described ΔLD15 dual CHOP::GFP and XBP1s::Turquoise UPR reporter 1096 
Chinese Hamster Ovary CHO-K1 cell lines (Kono et al., 2017) and have been authenticated 1097 
as CHO-K1 using the criteria of successful targeting of essential genes using species 1098 
specific CRISPR whole genome library, and sequencing of the wild-type or mutant alleles of 1099 
the genes studied that confirmed the sequence reported for the corresponding genome. The 1100 
cell lines have tested negative for mycoplasma contamination using a commercial kit 1101 
(MycoAlert (TM) Mycoplasma Detection Kit, Lonza). None of the cell lines is on the list of 1102 
commonly misidentified cell lines maintained by the International Cell Line Authentication 1103 
Committee. The CRISPR-Cas9-mediated mutagenesis strategy and the transient 1104 
transfection of GST-tagged IRE1LD was performed with CHO-K1 S21 dual UPR reporter cells 1105 
(Sekine et al., 2016). Cells were cultured in Ham’s nutrient mixture F12 (Sigma). All cell 1106 
media was supplemented with 10% (v/v) serum (FetalClone-2, Hyclone), 2 mM L-glutamine 1107 
(Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma). Cells were grown in tissue 1108 
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culture dishes or multi-well plates (Corning) at 37°C and 5% CO2. 1109 
Tunicamycin (Melford) treatment was at 2.5 μg/ml for 16 hours, 2-Deoxyglucose (2DG) 1110 
(Sigma) treatment at 4 mM for 16 hours and 4μ8c (Cross et al., 2012) treatment at 1111 
10 μM for 7 days. The drugs were mixed with pre-warmed culture medium and immediately 1112 
added to the cells by medium exchange. 1113 
Transfection 1114 
Cells were transfected using Lipofectamine LTX (Life Technologies) transfection reagent 1115 
with reduced serum medium Opti-MEM (Life Technologies) following the manufacturer’s 1116 
instructions. 1117 
Flow cytometry and fluorescence-activated cell sorting (FACS) 1118 
To analyse the effect of IRE1 variants expressed from the endogenous Ern1 locus on the 1119 
UPR (Fig. 1A, 1B, Figure 4, supplements 1A and 1B), flow cytometry was performed. Cells 1120 
were washed once in PBS and collected in PBS containing 4 mM EDTA. Single cell 1121 
fluorescent signals (20,000/sample) were analysed by dual-channel flow cytometry with an 1122 
LSRFortessa cell analyser (BD Biosciences). FACS was performed on either a Beckman 1123 
Coulter MoFloor a BD FACSMelody cell sorter. Cells were washed once in PBS and then 1124 
incubated 5 minutes in PBS supplemented with 0.5% BSA and 4 mM EDTA before sorting 1125 
into fresh media. CHOP::GFP fluorescence was detected with excitation laser at 488 nm , 1126 
filter 530/30 nm; XBP1s::Turquoise fluorescence with excitation laser 405 nm, filter 450/50 1127 
nm and mCherry fluorescence with excitation laser 561, filter 610/20. To generate clonal cell 1128 
lines stably expressing a version of IRE1 the transfected cells were treated with 1129 
2-Deoxyglucose to gate for cells showing high CHOP::GFP XBP1s::Turquoise fluorescence. 1130 
Gene manipulation and allele analysis 1131 
Cas9 guides were either manually designed following standard guidelines (Ran et al., 2013) 1132 
or taken from the CRISPy database (URL: http://staff.biosustain.dtu.dk/laeb/crispy/, (Ronda 1133 
et al., 2014). Cells were transfected with the Cas9 and guide constructs and grown for seven 1134 
days before they were analysed by flow cytometry or FACS. 1135 
For the in vivo mutagenesis strategy (Fig. 3B, 3C and Figure 3, supplement 1B) a series of 1136 
guides that tiled the two regions of interest, set A covering the putative loop (residues 308-1137 
362) and set B covering the tail (residues 368-444) was designed. Set A and set B guide-1138 
Cas9 encoding plasmids were transfected singly or in different pairwise combinations into 1139 
IRE1 wild-type expressing cells (CHO-K1 S21 CHOP::GFP, XBP1s::Turquoise dual reporter 1140 
cell line) and pooled to create population 0 (Fig. 3C). Rare de-repressing IRE1 mutants were 1141 
enriched from the mutagenised population by iterative rounds of FACS (population 1 and 2) 1142 
followed by a selection against clones that had acquired IRE1-independent 1143 
XBP1s::Turquoise reporter expression, as assessed by their unresponsiveness to the IRE1 1144 
inhibitor 4µ8c. Genomic DNA was extracted from final clones, PCR used to amplify the loci 1145 
of interest and the resultant products were sequenced. The genomic DNA was extracted 1146 
from cells by incubation in Proteinase K solution (100 mM Tris-HCl pH 8.5, 5 mM EDTA, 1147 
200 mM NaCl, 0.25% SDS, 0.2 mg/ml Proteinase K) overnight at 50˚C. Next, Proteinase K 1148 
was heat inactivated at 98˚C for 20 minutes before the supernatant was collected and used 1149 
as a template in PCR reactions before sequencing. To facilitate the interpretation of the 1150 
sequencing data, the changes in size of alleles modified by Cas9 was determined by 1151 
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capillary electrophoresis on a 3730xl DNA analyser (Applied Biosystems). For that, sample 1152 
preparation was performed with one of the oligonucleotides having a 5’ 6-carboxyfluorescein 1153 
(FAM) flurophore in the PCR reaction.  1154 
Creating clonal cell lines stably expressing IRE1 variants 1155 
The activity of IRE1 variants was analysed by introducing them into the endogenous Ern1 1156 
locus of CHO-K1 CHOP::GFP and XBP1s::Turquoise dual UPR reporter cells using a Ern1 1157 
null cell line (∆IRE1 as described in (Kono et al., 2017)). Cells were transfected with a Cas9-1158 
CRISPR guide construct targeting the Ern1 locus (UK1903) together with the respective 1159 
repair templates (UK2425 for chimeric J-IRE1, UK2426 for JQPD-IRE1, UK1968 for wild-type 1160 
IRE1, UK2384 for IRE1 ∆loop, UK2385 for IRE1 ∆tail, UK2386 for IRE1 ∆∆) and grown for 1161 
seven days before further analysis. Cells that successfully repaired the IRE1 locus were 1162 
selected by FACS by gating for cells exhibiting increased XBP1s::Turquoise fluorescence 1163 
after 2DG treatment. Cells transfected with J-IRE1 as repair template were additionally 1164 
transiently transfected with a plasmid encoding SubA wild-type, mutant or an empty vector 1165 
(UK1452, UK1459, UK1314 respectively) before FACS. Data shown in Fig. 4A and Figure 4, 1166 
supplement 1A was acquired after transient transfection using a mixed population of cells 1167 
and data shown in Fig. 1A, 1B, 1C, 4B and Figure 4, supplement 1B with clonal cell lines.  1168 
Mammalian cell lysis 1169 
Cell lysis was performed as described previously (Amin-Wetzel et al., 2017). All reagents 1170 
were kept on ice throughout. Cells were washed in PBS, removed from the culture dish in 1171 
PBS + 1 mM EDTA with a cell scraper and then pelleted at 370  g for 5 minutes at 4°C. 1172 
Cells were incubated in lysis buffer (1% Triton X-100, 150 mM NaCl, 20 mM HEPES-KOH 1173 
pH 7.5, 10% glycerol, 1 mM phenylmethylsulphonyl fluoride (PMSF), 4 μg/m Aprotinin, 1174 
2 μg/ml Pepstatin A and 2 μM Leupeptin) for 5 minutes. Next, the samples were clarified at 1175 
21,130 g for 10 minutes at 4°C. The supernatant was transferred to a fresh tube and protein 1176 
concentration measured with BioRad protein assay reagent (Bio-Rad). 1177 
 1178 
For BiP co-IP experiments non-specific binding of BiP to protein-A sepharose beads was 1179 
decreased by digitonin treatment (Le Gall et al., 2004) to remove non-membrane associated 1180 
BiP from cells prior to lysis. After pelleting, cells were washed in HNC buffer (50 mM 1181 
HEPES-KOH pH 7.5, 150 mM NaCl, 2 mM CaCl2) and then incubated in HNC + 0.1% (w/v) 1182 
digitonin (Calbiochem) for 10 minutes. Cells were then washed in HNE buffer (50 mM 1183 
HEPES-KOH pH 7.5, 150 mM NaCl, 1 mM EGTA) before proceeding to lysis using lysis 1184 
buffer supplemented with 10 mM MgCl2, 6 mg/ml glucose and 50 U/ml Hexokinase (H4502 1185 
Sigma) to deplete ATP and stabilise BiP-substrate interactions. 1186 
Immunoprecipitation (IP) and GST pull down assays 1187 
To analyse the amount of BiP co-immunoprecipitated with endogenously expressed IRE1 1188 
variants (Fig. 1C and 4B) or transiently transfected IRE1LD-GST variants (Fig. 4C), Protein A 1189 
sepharose 4B beads (Zymed Invitrogen) or Glutathione (GSH) Sepharose 4B beads (GE 1190 
Healthcare) were equilibrated in lysis buffer. Next, 20 μl beads per sample and anti-IRE1α 1191 
were added to lysates and left rotating for 1 hour at 4°C. The beads were then washed in 1192 
lysis buffer and residual liquid removed using a syringe. The protein from the beads was 1193 
eluted in SDS sample buffer containing 20 mM DTT. 1194 
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Antibodies 1195 
Anti-mouse IRE1α serum (NY200) was used for IP and immunoblot detection of endogenous 1196 
IRE1α (Bertolotti et al., 2000). An anti-hamster BiP antibody was used for immunoblot 1197 
detection of endogenous BiP (Avezov et al., 2013). Anti-GST serum was used for 1198 
immunoblot detection of GST fusion proteins (Ron and Habener, 1992). 1199 
Reducing/non-reducing SDS-PAGE and immunoblotting 1200 
Samples were run on standard polyacrylamide Tris-HCl gels and transferred to Immobilon-P 1201 
PVDF membrane (Pore size 0.45 μm, Sigma). Membranes were then blocked in 5% (w/v) 1202 
dried skimmed milk in PBS, washed in TBS with 0.1% Tween-20 and exposed to various 1203 
primary antibodies/antisera followed by incubation with IRDye fluorescently labelled 1204 
secondary antibodies. Imaging was carried out with using a LICOR CLx Odyssey infrared 1205 
imager. Coomassie-staining was carried out with Instant Blue (Expedeon). Signal 1206 
quantitation from SDS-PAGE gels or from immunoblots was carried out using the ImageJ 1207 
software (NIH). 1208 
Protein Purification 1209 
Human IRE1LD 1210 
His6-Smt3-IRE1
LD (UK2048, UK2079, UK2042, UK2370, UK2410, UK2411, UK2516, 1211 
UK2045, UK2304) and His6-Avitag-IRE1
LD (UK2412, UK2246, UK2459, UK2408, UK2458) 1212 
variants were encoded on a pET-derived vector (Novagen) as fusion proteins and expressed 1213 
in T7 Express lysY/Iq E. coli cells (NEB). IRE1LD Q105C variants (UK2045, UK2304) used to 1214 
make disulphide-linked dimeric IRE1LD Q105C species were expressed in Origami B(DE3) cells 1215 
(Novagen). 1216 
Protein purification was performed as described in (Amin-Wetzel et al., 2017). Bacterial 1217 
cultures were grown at 37°C in LB medium containing 100 mg/ml ampicillin until an OD600nm 1218 
of 0.6-0.8 was reached. Expression was induced with 0.5 mM IPTG and the cells were 1219 
incubated for 16 hours at 18°C. After sedimentation of the cells by centrifugation the pellets 1220 
were resuspended in TNGM buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 10% glycerol, 1221 
1 mM MgCl2). The cell suspension was supplemented with 0.1 mg/ml DNaseI and protease 1222 
inhibitors (2 mM PMSF, 4 mg/ml Pepstatin, 4 mg/ml Leupeptin, 8 mg/ml Aprotinin) and lysed 1223 
by repeated passage through a high-pressure homogenizer (EmulsiFlex-C3, Avestin). After 1224 
clarification of the lysates by centrifugation at 20,000  g for 30 minutes the supernatant was 1225 
removed and incubated for 60 minutes at 4°C with Ni-NTA agarose (Qiagen) (0.5 ml per liter 1226 
of bacterial culture). The matrix was washed two times with 50 ml of TNGMI wash buffer 1227 
(50 mM Tris-HCl pH 7.4, 500 mM NaCl, 10% glycerol, 1 mM MgCl2, 20 mM imidazole). The 1228 
matrix was transferred to a gravity-flow column and the flow-through was collected after a 1229 
wash with one bed volume of elution buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1230 
10% glycerol, 250 mM imidazole). The protein solutions were concentrated using 30 kDa 1231 
MWCO centrifugal filters (Amicon Ultra; Merck Millipore), flash frozen and stored at -80˚C. 1232 
For the preparation of UK2042, UK2045, UK2410, UK2411 and UK2516 1.5 µg/ml His6-Ulp1 1233 
(UK1249) and 1 mM TCEP were added to the eluates and incubated overnight at 4°C, whilst 1234 
being dialysed against HKM buffer (50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM 1235 
MgCl2). To remove the cleaved His6-Smt3-tag and the His6-Ulp1 the solution was again 1236 
incubated with Ni-NTA agarose for 60 minutes at 4°C. After passing the sample through a 1237 
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gravity-flow column the final eluate was collected, concentrated using 30 kDa MWCO 1238 
centrifugal filters, flash frozen and stored at -80˚C.  1239 
For the preparation of UK2304, the dialysis overnight was performed against TN buffer 1240 
(150 mM NaCl, 50 mM Tris-HCl pH 7.4). After removal of uncleaved protein and His6-Smt3 1241 
the protein solution was then diluted to 75 mM NaCl, 50 mM Tris-HCl pH 7.4, 10 mM 1242 
imidazole and bound to an anion exchange column. The protein was eluted in 10 mM Tris-1243 
HCl pH 7.4 50-500 mM NaCl and then incubated with 5 mM oxidised glutathione overnight. 1244 
The sample was then separated on a Superdex 200 10/300 GL gel filtration column 1245 
equilibrated in TN buffer and appropriate fractions collected and concentrated using 30 kDa 1246 
MWCO centrifugal filters, flash frozen and stored at -80˚C. 1247 
The purification of the FRET probes (UK2048, UK2076, UK2412, UK2370) was performed 1248 
as described above with 1 mM TCEP contained in all buffers. Eluted fractions were buffer 1249 
exchanged into HKMT buffer (50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM MgCl2, 1250 
1 mM TCEP) using a CentiPure P10 desalting column (Generon) and labelled with 3-fold 1251 
molar excess of Oregon Green-iodoacetic acid (ThermoFisher) or TAMRA-maleimide 1252 
(Sigma) to make IRE1LD R234C-OG (UK2048), IRE1LD R112C-TMR (UK2076), J-IRE1S112C-TMR 1253 
(UK2412) and IRE1LD ∆∆ S112C-TMR (UK2370). The reaction proceeded at room temperature 1254 
in the dark overnight and was quenched by the addition of 5 mM DTT. The reaction mixture 1255 
was passed through a CentiPure P10 gravity-desalting column (Generon) equilibrated in 1256 
HKM buffer and afterwards through a Superdex 200 10/300 GL gel filtration column 1257 
equilibrated in HKG (50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10% (v/v) glycerol) buffer. 1258 
Appropriate fractions were collected, concentrated, flash frozen and stored at -80˚C.  1259 
For the streptavidin pull down (Fig. 1D and Fig. 5B) and the Bio-Layer Interferometry (BLI) 1260 
measurements (Fig. 5A and Figure 5, supplement 1A and 1B), chimeric J-IRE1LD (UK2408), 1261 
J-IRE1LD ∆∆ (UK2458), J-IRE1LD P108A (UK2428) and J-IRE1LD Q105C SS(UK2558), wild-type 1262 
IRE1LD (UK2246) and IRE1LD ∆∆ (UK2459) were biotinylated enzymatically with E. coli BirA to 1263 
create biotinylated J-IRE1LD-bio and IRE1LD-bio variants, respectively. 1264 
Hamster ERdj4 1265 
Expression and purification of ERdj4 and variants was performed according to the protocol 1266 
previously described in (Amin-Wetzel et al., 2017). The constructs were expressed as fusion 1267 
proteins with an N-terminal His6-Smt3 (UK2012 for wild-type ERdj4) or with both, an 1268 
N-terminal His6-Smt3 and C-terminal MBP (UK2108 for wild-type and UK2119 for QPD 1269 
ERdj4) in Origami B(DE3) cells. Cells were grown and lysed as described above for His6-1270 
Smt3 tagged proteins. Ni-NTA chromatography was performed as described above. His6-1271 
Smt3-ERdj4-MBP variants were further purified on a S200 10/300 GL column equilibrated in 1272 
HKM buffer. 1273 
Hamster BiP 1274 
BiP and BiP variants (UK173, UK182, UK984) were purified as previously described in 1275 
(Petrova et al., 2008; Preissler et al., 2015a). 1276 
Streptavidin pull down assays 1277 
To assess BiP binding to IRE1LD variants in the presence and absence of J-domain-1278 
mediated hyper-affinity (Fig. 1D and Figure 5B, respectively), 20 μl Dynabeads MyOne 1279 
Streptavidin C1 (Thermo Fisher Scientific) per sample were used. Analysis was performed in 1280 
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HKMGTw buffer (50 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM MgCl2, 10% (v/v) 1281 
glycerol, 0.05% TWEEN-20). Reactions contained 5 μM biotinylated IRE1LD proteins 1282 
(UK2246, UK2408, UK2459), 8 μM ERdj4 (UK2012), 30 μM BiP variants (UK173, UK182, 1283 
UK984), and 2 mM ATP. In experiments conducted in presence of a J-domain the samples 1284 
were incubated for 20 minutes at 30°C. In experiment conducted in absence of a J-domain 1285 
for 16 hours at 4°C. Next, the samples were clarified at 21,130  g for 5 minutes and an 1286 
excess of ice cold 1 mM ADP was added to the supernatant followed by the addition of 1287 
Dynabeads. Binding was performed for 45 minutes at 4°C followed by washing in assay 1288 
buffer supplemented with 1 mM ADP (for the ATP wash 2 mM ATP was used instead). The 1289 
samples were eluted with 1x SDS sample buffer. 1290 
Analytical size-exclusion chromatography (SEC) 1291 
To assess the oligomeric state of wild-type IRE1LD (UK2042), IRE1LD W125A (UK2411) and 1292 
IRE1LD P108A (UK2410) and IRE1LD ∆∆ (UK2516) in presence and absence of MPZ-N peptide 1293 
(GeneScript, Piscataway, NJ), SEC was performed (Fig. 2A and 2B, Figure 2, supplement 1294 
1A and Figure 5, supplement 1C). Samples were run through a SEC-3 HPLC column (300 Å 1295 
pore size; Agilent Technologies) on an Agilent infinity HPLC system equilibrated in HKM 1296 
buffer at a flow rate of 0.3 ml/min. Samples were pre-incubated in a final volume of 20 µl for 1297 
30 minutes at 30°C before clarification at 21,130  g for 5 minutes and subsequent injection 1298 
of 10 µl. Runs were performed at 25°C and A280 absorbance and TAMRA (TMR, excitation 1299 
544 nm and emission 572 nm) traces were recorded. 1300 
Bio-Layer Interferometry (BLI) experiments 1301 
Experiments were performed on an Octet RED96 (Pall ForteBio) in HKM buffer 1302 
supplemented with 0.05% Triton X-100. In the sequential dipping experiments (Fig. 5A and 1303 
Fig. 5, supplement 1A and 1B), streptavidin biosensors were loaded with the indicated 1304 
biotinylated IRE1LD variants (UK2246, UK2428, UK2558, UK2459, UK2408, UK2458) to 1305 
approximately 1 nm displacement, washed in assay buffer, and then sequentially dipped in 1306 
wells containing the indicated analytes. For the two-component system (Fig. 5A and Fig. 5, 1307 
supplement 1B) with the chimeric J-IRE1LD fusions 0.15 or 0.5 µM BiP wild-type (UK173), 1308 
0.5 µM BiPV461F (UK182) and 2 mM ATP were used and for the three-protein system (Fig. 5, 1309 
supplement 1A) 2 µM BiP (UK172), 6.8 µM ERdj4 full-length (UK2012) or J-domain 1310 
(UK2041) and 2 mM ATP. After each association the sensor was dipped into buffer 1311 
containing 2 mM ATP to allow for BiP dissociation. Data were normalised to the signal after 1312 
the first wash step. 1313 
Kinetic FRET experiments 1314 
To assess the effect of a fused J-domain to IRE1LD (Fig. 1E) or the introduction of deletions 1315 
into the IRE1LD on Erdj4 and BiP-mediated monomerisation (Fig. 5C) kinetic FRET 1316 
measurements were performed. For this, heterodimeric FRET pairs consisting of an OG-1317 
labelled wild-type donor molecule combined with a TMR-labelled mutant acceptor molecule 1318 
were employed. Although this experimental setup reduces the dynamic range of the 1319 
measurements this is compromised by the increased accuracy of detected donor 1320 
fluorescence due to a constant IRE1LD-OG donor molecule. IRE1LD-OG donor (UK2048-OG) 1321 
and IRE1LD-TMR acceptor (UK2076-TMR, UK2412-TMR, UK2370-TMR) molecules were 1322 
combined at a 1:2 ratio and incubated at room temperature in the dark for two hours. In 1323 
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Fig. 1E 30 µM BiP, 2.5 µM ERdj4 (UK2108), and 0.2 µM IRE1LD-FRET pair were combined 1324 
in HKMGTw buffer and incubated for 30 minutes. To initiate the reaction, 2 mM ATP with an 1325 
ATP regeneration system (8 mM phosphocreatine, 0.016 mg/ml creatine kinase) was added. 1326 
In Fig. 5C, 30 µM BiP, 2.5 µM ERdj4 full-length (UK2108) or J-ERdj4 (UK2041), and 0.2 µM 1327 
pre-equilibrated IRE1LD-FRET pair were combined in HKMGTw buffer. The donor 1328 
fluorescence was followed with a CLARIOstar plate reader (excitation: 470-15 nm, emission: 1329 
524-20 nm) recording signals every 30 seconds. The donor fluorescence was background 1330 
subtracted arising from a well containing buffer only and analysed with the Prism GraphPad 1331 
7.0 software. 1332 
Differential scanning fluorimetry (DSF) 1333 
DSF experiments were performed on a CFX96 Real-Time System (Bio-Rad). Reactions 1334 
were transferred into 96-well qPCR plates (Thermofisher) (final volume 25 µl). Protein 1335 
concentrations were 5 µM, ligands at the concentration indicated in the figure (62.5-1336 
1000 µM), and SYPRO Orange (Thermofisher) dye at a 10x concentration in HKM buffer. 1337 
Where indicated 1 mM TCEP was included. Over a temperature range of 20-95ºC 1338 
fluorescence of the SYPRO Orange dye was monitored using the SYBR-FAM filter set. Data 1339 
was then analysed in Prism GraphPad 7.0, with melting temperature calculated as the global 1340 
minimum of the negative first derivative of the respective fluorescent unit melt curves. Data 1341 
shown in Fig. 2, supplement 1D indicate a correlation between the monomer-dimer 1342 
equilibrium and the Tm of IRE1
LD. In line with that, titrational analysis of IRE1LD and variants 1343 
reported on an increased Tm at higher protein concentrations, however it did not result in a 1344 
two state transition representing the monomer and the dimer because of oligomerisation 1345 
(data not shown). Moreover, the lower Tm of the monomeric variants could reflect an intrinsic 1346 
destabilisation of the protein caused by the point mutation. 1347 
Fluorescence polarisation (FP) 1348 
To characterise the binding of FAM labelled MPZ-N peptide [5-FAM-LIRYCWLRRQAA) (as 1349 
described in (Karagoz et al., 2017), from GeneScript, Piscatawy, NJ] to IRE1LD or disulphide-1350 
linked IRE1LD Q105C SS. (Fig. 2D). FP was measured with a CLARIOstar plate reader. Using 1351 
excitation at 496 nm and measuring emission at 519-550 nm, parallel and perpendicular 1352 
fluorescence of the FAM fluorophore was detected. Whilst FAM-MPZN was kept at 100 nM 1353 
in reactions the concentrations of IRE1LD variants are detailed in the legend of Fig. 2D. 1354 
Samples containing the respective components were prepared in 25 μl and then 20 μl were 1355 
transferred to a black flat-bottomed 384 well plate and incubated for 30 minutes prior to 1356 
reading. Fluorescence readings were corrected by subtracting fluorescence from a well 1357 
containing only buffer. The average of 3 readings (spaced at 30 seconds intervals) per well 1358 
was taken as one repeat and the average of three independent repeats was used for Fig. 1359 
2D. Anisotropy was calculated according to equation 1: 1360 
𝐴 =
𝐼𝑝𝑎𝑟𝑎−𝐼𝑝𝑒𝑟𝑝
𝐼𝑝𝑎𝑟𝑎+2𝐼𝑝𝑒𝑟𝑝
     (1) 1361 
The data was fit to equation 2: 1362 
𝑟𝑓𝑟𝑒𝑒 +
(𝑟𝑚𝑎𝑥−𝑟𝑓𝑟𝑒𝑒)
ℎ
[𝑋]ℎ+𝐾ℎ
    (2) 1363 
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Whereby rfree represents anisotropy in the absence of protein, rmax the theoretical maximal 1364 
anisotropy, [X] the protein concentration and h the hill-coefficient. Curve fitting was per- 1365 
formed with Prism GraphPad 7.0 and minimal constraints to obtain K1/2max values with R
2 1366 
values > 0.9. As this equation does not consider the equilibria between IRE1LD dimers and 1367 
oligomers, the K1/2max value does not reflect the dissociation constant. 1368 
Hydrogen exchange mass spectrometry (HX-MS) 1369 
For Fig. 6A and Figure 6, supplement 1A, 5 µM wild-type IRE1LD (UK2042) or monomeric 1370 
IRE1LD W125A (UK2411) and IRE1LD P108A (UK2410) were pre-incubated for 30 minutes at 30˚C 1371 
in HKM buffer. The samples were then diluted 1:20 in D2O buffer supplemented with 10 mM 1372 
ADP (HKM buffer was lyophilised and re-dissolved in pure D2O at least three times) and 1373 
incubated for 30 and 300 seconds at 30°C. Deuterated samples were quenched 1:1 with ice-1374 
cold quench buffer (2% formic acid), immediately subjected to LC-MS using an Agilent UPLC 1375 
and a MaXis mass spectrometer (Bruker). For each experiment at least one unexchanged 1376 
sample and one fully deuterated control were measured. The unexchanged protein sample 1377 
was diluted 1:20 in H2O buffer. The fully deuterated sample (protein in HKM buffer 1378 
containing 6 M guanidine hydrochloride, lyophilised and re-dissolved in pure D2O at least 1379 
three times) was treated as the other samples. For HX-MS experiments presented in 1380 
Fig. 6C, Figure 6, supplements 1B and 1C, 5 µM wild-type IRE1LD (UK2042) or IRE1LD ∆∆ 1381 
(UK2516) was incubated with 30 µM BiP wild-type (UK173) or V461F mutant (UK182), 6 µM 1382 
ERdj4 wild-type (UK2108) or ERdj4 QPD mutant (UK2119) and 2 mM ATP in HKM buffer. 1383 
Dilution in D2O buffer and subsequent steps were performed as described above. Data 1384 
analysis was performed manually (Data Analysis 4.1, Bruker). 1385 
HX-MS data analysis of the bimodal distributed isotope clusters 1386 
In order to observe an amide hydrogen exchange, a structure-specific H-bond between a 1387 
peptide backbone amide hydrogen and an H-bond acceptor has to open. This opening 1388 
occurs by unfolding of secondary structures within the native conformation of the protein 1389 
according to equation 3: 1390 
    (3) 1391 
Hereby, F and U indicate the folded and unfolded state of the structural element, 1392 
respectively. The conversions between these conformations are determined by kop and kcl, 1393 
representing the opening and closing rate constants. The intrinsic chemical exchange rate is 1394 
indicated by kch. 1395 
There are two extreme cases, distinguishing the so-called EX1 and EX2 exchange regimes. 1396 
In case of EX1 kcl is much smaller than kch. Therefore, all amide protons exchange at once 1397 
upon unfolding and the observed rate is practically equal to the opening rate kop of the 1398 
structural element. This type of exchange kinetics is characterised by a bimodal distribution 1399 
of the isotope peaks in peptic mass spectra showing two separate, interconverting 1400 
subpopulations (Fig. 7, supplement 1A). Notably, the EX1 exchange regime occurs only 1401 
rarely under native conditions and is more likely to be observed in presence of chemical 1402 
denaturants as they decrease the closing rate kcl without affecting the intrinsic chemical 1403 
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exchange rate kch by interfering with H-bond and hydrophobic core formation. EX2 is most 1404 
commonly observed, as under native state conditions kcl is generally much greater than the 1405 
intrinsic chemical exchange rate kch. Hence, many opening and closing cycles are necessary 1406 
in order to exchange all amide protons to deuterons, which is visible by a gradual increase of 1407 
the average mass in the peptic mass spectra whilst the isotopic distribution remains roughly 1408 
the same (Rist et al., 2003). By comparing IRE1LD with the monomeric variants we identified 1409 
regions exhibiting increased deuteron incorporation in the monomeric state of the protein, 1410 
with some of them revealing bimodal distributions of the isotope clusters. In order to 1411 
calculate the contribution of each subpopulation to the peak intensities an equation for two 1412 
Gaussian distributions was fitted to the isotope peak maxima versus m/z plots using the 1413 
Prism GraphPad 7.0 software: 1414 
𝐼 =
𝐴1
σ∙√2𝜋
∙ 𝑒−
1
2
(
µ−µ1̅̅̅̅
𝜎
)
2
+
𝐴2
𝜎∙√2𝜋
∙ 𝑒−
1
2
(
µ−µ2̅̅̅̅
𝜎
)
2
     (4) 1415 
 1416 
Hereby, A1/2 represents the area of the two peaks; µ, the m/z values; µ̅, the means of the 1417 
Gaussian distributions, representing the centroid of each of the two subpopulations; and σ, 1418 
the standard deviation of the Gaussian distributions, corresponding to the width of the 1419 
isotope peak distribution. For each peptide exhibiting a bimodal distribution all intensity 1420 
values belonging to one incubation time in D2O were globally fitted assuming that σ and are 1421 
constant. Independent experiments were treated independently. Next, the fitted parameters 1422 
A1/2, and σ were used to calculate the proportion of the low and high mass subpopulation for 1423 
each individual isotope peak. 1424 
Crystallisation, data collection and structure determination 1425 
Initial crystals were obtained by screening commercial crystallisation plates via 200 nl protein 1426 
(350 µM) plus 200 nl well solution in 96-well sitting drop plates at 20°C. The best diffraction 1427 
dataset was collected from a crystal grown in 9% MPD, 0.1 M HEPES-KOH pH 7.5 1428 
microseeded (D'Arcy et al., 2007) from diluted initial crystals in 20% MPD, 0.1 M 1429 
HEPES-KOH pH 7.5. Crystals were briefly soaked into 9% MPD, 0.1 M HEPES-KOH pH 7.5, 1430 
25% (v/v) glycerol and cryocooled in liquid nitrogen. Diffraction data was collected at 1431 
beamline I04-1 in the Diamond Synchrotron Light Source (DLS) and processed by the XIA2 1432 
pipeline (Winter, 2010) implementing Dials (Winter et al., 2018) for indexing and integration, 1433 
Pointless for space group determination, and Aimless for scaling and merging (Evans, 1434 
2011). The structure was solved by searching the published IRE1LD core structure (PDB 1435 
2HZ6) using Phaser (McCoy et al., 2007). One molecule of IRE1 was found in one 1436 
asymmetric unit, but the electron density around Cys105 and the SG-SG bond length 1437 
suggested that Cys105 formed a disulphide bond with the symmetric Cys105. Further 1438 
refinement was performed iteratively using COOT (Emsley et al., 2010) and refmac5 (Winn 1439 
et al., 2001) (Table 1) in CCP4i2 interface (Potterton et al., 2018) and phenix.refine (Adams 1440 
et al., 2010). MolProbity (Chen et al., 2010) was consulted throughout the refinement 1441 
process. Molecular graphics were generated with PyMOL Molecular Graphics System, 1442 
Educational-use-only version 4.5 Schrodinger, LLC). 1443 
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